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Abstract
Mammalian thioredoxin reductase (TR) contains the rare amino acid
selenocysteine (Sec), which is essential for the enzyme’s catalytic activity. Substitution
of the catalytic Sec residue for a cysteine (Cys) residue, results in a drop in kcat of 100fold. Homologous high molecular weight TRs from other eukaryotes such as D.
melanogaster and C. elegans, have naturally evolved a Sec to Cys substitution in their
active sites and these enzymes function with high catalytic activity without the need for a
Sec residue. Thus, various TRs can catalyze an identical reaction with either a Cys or
Sec residue. A natural assumption in the field has always been that the lower
nucleophilicity of a Cys thiol, relative to the selenol of Sec, is the reason for the much
lower activity of the mammalian Cys-containing mutant. However, here I provide an
alternative explanation. High Mr TRs contain either a Cys-Cys or Cys-Sec dyad that
forms an eight-membered ring in the oxidized state during the redox cycle of the enzyme.
These eight-membered ring structures are rare in protein structures, presumably due to
the strain induced in the intervening peptide bond between the Cys residues. Here I take a
“chemical approach” to studying the enzyme mechanism of TR by breaking it into two
pieces. This approach is possible because of TR’s structural and mechanistic similarity to
glutathione reductase (GR). In comparison to GR, TR contains an additional thioldisulfide exchange step resulting from the presence of a sixteen amino acid C-terminal
extension containing either a vicinal disulfide bond or vicinal selenylsulfide bond. This
additional thiol-disulfide exchange step is in the form of the reduction and opening of the
eight-membered ring motif. I have constructed a truncated version of the enzyme lacking
the amino acid sequence possessing the ring motif so that I could isolate this ring-opening
step from the rest of the catalytic cycle by using peptide disulfides/selenylsulfides as
substrates. The results of this study using peptide substrates show that the ring opening
step is the step of the catalytic cycle that is most effected by Sec to Cys substitution
because the higher pKa of the Cys thiolate in comparison to the Sec selenolate means that
the Cys residue must be protonated in this step.
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Chapter 1
Introduction to Thioredoxin Reductase
Introduction
Redox Systems
Oxygen is the molecule of aerobic life. Life uses the energy in molecular oxygen
to drive ATP synthesis which in turn fuels all the other critical chemical reactions
occurring in an organism. A side of effect of oxygen is oxidation and formation of
reactive oxygen species. The cell must deal with these oxidation products or havoc will
result upon the cellular machinery. To maintain cellular redox homeostasis two systems
have evolved: the thioredoxin system and the glutaredoxin system (1). Both of these two
systems use gradients of electron potential to act as an electron flow pathway to
ultimately reduce a target substrate.

In each system, NADPH, acts as the primary

hydrogen donor because its redox potential is extremely low (2).
The glutaredoxin system
The glutaredoxin system consists of glutaredoxin (grx), glutathione, NADPH, and
glutathione reductase. In this system electrons are transferred from NADPH, through
glutathione reductase, which reduces its substrate oxidized diglutathione (GSSG) to two
molecules of glutathione (GSH), which then in turn act upon grx yielding its reduced
form. Grx functions to deglutathionylate proteins, similarly as phosphatases
dephosphorylate proteins (3).

This system acts to maintain high levels of reduced

glutathione which acts as a thio-disulfide redox buffer (4). The pool of glutathione is
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kept almost exclusively reduced, with ratios of up to 200:1 reported compared to the
oxidized (5).
The Thioredoxin System
In addition to the glutaredoxin system, the thioredoxin system functions as a
critical antioxidant system that is also responsible for maintaining the reduced cellular
environment. This system is composed of two oxidoreductase enzymes thioredoxin (Trx)
and thioredoxin reductase (TR) as well as the reducing cofactor NADPH. (6)
Trx is a small protein of approximately 12 kDa that is responsible for reducing
many intracellular cellular targets, and hence must be constantly cycled back to the
reduced state by TR (6-8). The Trx active site consists of a conserved CXXC motif (9)
that when oxidized forms a disulfide bond.

The reduced, dithiol form of Trx is

responsible for being the hydrogen donor of many substrates, but was first described for
its role in the enzymatic synthesis of deoxyribonucleotides by ribonucleotide reductase in
E.coli (10). It has since been described to be involved in many reactions in which
disulfide bond formation results, such as with methionine sulfoxide reductase (11) and
peroxiredoxins (12).
The redox regulation of various proteins by the Trx system has also been
recognized. For instance, Trx must reduce a single cysteinyl residue, to allow for the
association of NF-κB subunit p50 to its DNA target sequence (13). Trx catalyzed
reduction also results in the activation of many transcription factors, with some examples
consisting of the tumor suppressor p53 (14), the estrogen receptor (15), and glucocortcoid
receptor (16).
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Thioredoxin Reductase
The buildup of oxidized Trx is the consequence of the reduction of cellular
disulfides. For Trx to maintain its function, Thioredoxin reductase (TR) (EC 1.6.4.5) an
essential part of the thioredoxin system, must act as an equalizing factor to maintain Trx
in its reduced state, to prevent the upsurge of the oxidized Trx pool (17). TR is a member
of the family of pyridine nucleotide-disulfide reductases, which function to maintain
cellular redox homeostasis (18).

Other enzymes in this family include glutathione

reductase, lipoamide dehydrogenase, and mercuric ion reductase, which are all highly
conserved structurally. Members of this family are all homodimers that accept reducing
equivalents, usually in the form of NADPH, which donates a hydride to an enzyme bound
cofactor (FAD), which in turn forms a charge-transfer complex with an enzyme disulfide
and then transfers the electrons to the target substrate (19) (Figure 1A).
Two forms of TR have evolved in nature, low and high molecular ratio (Mr)
enzymes. Low Mr TRs (35 kDa) are found in prokaryotes, archaea and lower eukaryotes,
while high Mr TRs (55 kDa) are found in higher eukaryotes. Both forms catalyze the
identical reaction, though different catalytic mechanisms have evolved for each. (20, 21).
The mechanism of the low Mr TR, from E. coli (EcTR) has been reviewed by
Williams (22). The general mechanism of this enzyme is the same as the other family
members such as glutathione reductase (GR) (Figure 1B). However there are several
distinct differences between them. In addition to the noticeable differences in the Mr
between the two classes, the crystal structure indicates that the mechanism requires a
large conformational change upon binding of NADPH to the NADPH binding domain. A

3

rotation of 66° is necessary to orient the pyridinium ring in proximity of the FAD for
electron transfer (23). This conformation change is not observed in the high Mr TRs.
The high Mr TRs contain an additional C-terminal redox center compare to EcTR
and other family members. This C-terminal redox center contains a dithiol/disulfide
redox pair, which first accepts two electrons from the N-terminal dithiol/disulfide, and it
is this C-terminal motif that catalyzes reduction of the target substrate Trx (21) (Figure
1C). This C-terminal redox center varies from species to species.
This reaction scheme is highly conserved among this family of enzymes,
with GR and TR sharing the highest similarity. The functional enzymatic unit is a
homodimer. NADPH binds to the NADPH binding domain transferring electrons in the
form of a hydride to a FAD cofactor non-covalently associated to the enzyme. The
isoalloxazine ring of the flavin interacts with a conserved N-terminal redox center of
sequence CICVNVGCCT. This redox center must be reduced and results in the formation
of a charge-transfer complex with the FAD and the C-terminal Cys residue (abbreviated
as CysCT) from the N-terminal redox center. The N-terminal interchange CysIC of the
redox center then forms a thiolate which is capable of nucleophilically attacking an
incoming disulfide substrate and forming a mixed disulfide, causing release of the first
leaving group. During this step a conserved acid/base histidine, from the opposing
subunit, stabilizes the leaving group by donation of a proton. The CysCT residue then
completes the reaction by resolving the mixed disulfide, resulting in release of the
substrate and reoxidation of the N-terminal redox center. For GR the disulfide substrate
is GSSG, and results in the release of two GSH and a recycled enzyme. In the case of
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TR, this same N-terminal disulfide/dithiol redox center transfers its reducing equivalents
to a C-terminal dithiol/disulfide redox center on the opposite subunit, which can be
considered analogous to the disulfide substrate, except that it is tethered to the enzyme.
The “release” of a reduced C-terminus results in the continuation of its catalytic cycle
through an additional step, reduction of its native substrate Trx before it is recycled.
High Mr TRs have two particularly interesting features concerning their Cterminal redox center.

In some higher eukaryotes, including mammals, it contains

selenium in the form of selenocysteine (Sec, U) – the 21st amino acid as the penultimate
amino acid (24), while other eukaryotic homologs have replaced the Sec residue with a
conventional cysteine (Cys) residue. The second interesting feature concerning their Cterminal redox center, involves the Sec or Cys residue as part of a vicinal selenylsulfide
or a rare vicinal disulfide bridge as part of their catalytic cycles (25, 26). The next
section will discuss these unique features.
Selenium as Selenocysteine
Selenium is an essential trace element present in all kingdoms of life. In its
elemental form selenium is toxic so it must be converted to low MW compounds such as
selenodiglutathione, methylselenol, selenide, selenomethionine and Sec by plants (27).
The most biologically active form of selenium is in the form of Sec, a Cys analog. At
physiological pH, these two amino acids have differing ionization states. Sec is ionized
and more highly reactive than Cys, while Cys is normally more stable and protonated in
its thiol form. This is due to Sec’s lower pKa of 5.3 compared to Cys (8.2) (28). Sec
becomes biologically active upon its incorporation into selenoproteins.
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The human

selenoproteome consists of 25 known selenoproteins (29). Of these selenoproteins, the
most characterized are glutathione peroxidases (GPx), iodothyronine deiodinases (DIO),
selenophosphate synthethetses 2 (SPS2), and TR, and all have oxidoreductase functions
(30).
Sec incorporation was first described being coded for by the opal codon UGA in
mouse glutathione peroxidase (31). Sec is synthesized through a serine intermediate on
its own unique tRNA, named tRNA[Ser]Sec (32, 33). The tRNA[Ser]Sec is loaded with serine
via seryl-tRNA synthase.

The loaded seryl-tRNA[Ser]Sec is then phosphorylated by

phosphoseryl tRNA kinase resulting in a phosphoseryl-tRNA[Ser]Sec.

To finish the

synthesis of Sec, Sec synthase reacts with the activated selenium donor,
monoselenophosphate, and the phosphoseryl-tRNA[Ser]Sec to yield Sec-tRNA[Ser]Sec (34).
To decode the UGA codon as a sense codon more than just the Sec-tRNA[Ser]Sec is
required. A secondary RNA stem-loop structure termed the Sec Insertion Sequence
(SECIS) element must be present, otherwise translation will result in termination. In
eukaryotes, the SECIS element is locate within the 3′-untranslated region (UTR) of the
mRNA (35). Additionally, specific Sec-decoding protein factors are needed such as Secspecific elongation factor (mSelB/eEFSec) (36, 37) and the SECIS-binding protein
(SBP2) (38, 39) for UGA decoding. The Sec-decoding apparatus recently had some new
additions, three additional proteins, the soluble liver antigen protein (SLA), Secp43 (the
43 kDa RNA-binding protein) (40), and the ribosomal protein L30 (41).
Selenocompounds have shown effectiveness in the treatment and prevention of
cancers leading to the search for therapeutic agents. TR has been proposed as a good
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anticancer target because this enzyme is necessary for cancer cell proliferation and has
been shown to be up-regulated in some cancer cell lines. The development of TR
inhibitors is an area of ongoing research, with several examples (reviewed in (17))
including nitrosoureas (42), cisplatin (43), the antitumor quinoid compounds such as
diaziquone and doxorubicin (44, 45). These compounds are all believed to interact with
the C-terminal active site thiol or selenol, and disrupt TR’s ability to recycle Trx, leading
to an oxidized cellular milieu.
Vicinal Disulfide Bonds
The other unique characteristic of the high Mr TR involves formation of either a
vicinal selenylsulfide or disulfide bridge on its C-terminus. In the Brookhaven Protein
Data Bank (PDB), a disulfide bond between neighboring Cys residues, (i, i + 1), is a rare
occurrence. In a study by Pongor and coworkers, there were only 32 occurrences of this
type of disulfide bond from 28,000 deposited structures (46).

The reason for the

infrequency of this type of disulfide bond is most likely due to the strain imparted on the
intervening peptide bond between adjacent half-cystinyl residues (47). This strain is due
to the existence of an eight-membered ring motif which contains a central amide bond
possessing partial double bond character. The ring strain imparts flexional torsion onto
the region of a peptide or protein where it is found in nature (48, 49). For example, NMR
studies have indicated that the most flexible part of human and bass hepcidin, as well as
the Janus-faced atracotoxin (J-ACTX) is the region of the protein where this ring is found
(50-52).
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This eight-membered ring motif almost always exists as part of a type VIII β-turn,
helping to stabilize this type of high energy turn structure (46). It is also found in various
enzymes such as methanol dehydrogenase, mercuric ion reductase, as well as TR (53-55).
In these systems, the Cys-Cys dyad cycles between reduced and oxidized states as part of
a redox cycle. In addition to a catalytic role for this motif, it has been proposed that this
flexible ring is part of a conformational switch, controlling active and inactive states of
the protein. This is apparently the case in the nicotinic acetylcholine receptor where it
has been proposed that switching between cis and trans forms of the ring regulates the
on/off state of the receptor (49, 56). A regulatory role for this motif has also been
proposed for cytochrome C oxidase from Utricularia (57).
The sequences of the high Mr TRs C-terminal redox center motif varies from
species to species. The mammalian enzyme is of particular interest because its Cterminal redox center contains Sec as part of a conserved tetrapeptide GCUG motif (24,
58). The Sec residue of this motif has been shown to be essential for function and is
thought to impart the enzyme with broad substrate specificity other than its natural target
of Trx including hydrogen peroxidase activity (59).
Many TRs lack Sec, and are able to catalyze the reduction of the catalytic
disulfide bond of Trx with a Cys residue in place of Sec. For example, in the case of the
TR from Drosophila melanogaster (DmTR), the enzyme contains a C-terminal SCCS
motif and this enzyme can reduce its cognate Trx with high efficiency, thus
demonstrating that the reaction can be catalyzed without the need of a selenium atom
(25). It has recently been proposed that the reason that DmTR can function with high
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catalytic efficiency using Cys in place of Sec is that the flanking serine residues increase
the nucleophilicity of the thiol-nucleophile by mediating proton transfer from the
attacking thiolate to the leaving group sulfur atom of the substrate (60). Mutation of the
N-terminal serine residue to a glycine residue had little effect on catalytic parameters,
while mutation of the C-terminal serine to a glycine residue decreased kcat by two-thirds.
Thus it seems that for DmTR, the C-terminal serine residue plays some role in catalysis.
However, not all TRs in which the Sec residue has been replaced with Cys
contain flanking serine residues. The TR from Anopheles gambiae (AgTR) contains an
N-terminal threonine, and in the case of the mitochondrial TR from C. elegans (CeTR2)
the flanking residues are glycine (61, 62).

Proposal /Specific Aim
With the unique features of TR C-terminus being variable between species I am
interested in studying the role of the vicinal Cys disulfide eight-membered ring motif.
Since this structure has been implicated in being a rare structure in nature, I want to
evaluate the importance of this eight-membered structure in the catalysis of TR. The
residues that compose the ring are known to be essential for activity, however to date no
one has evaluated the role of the ring structure in the catalytic cycle, therefore I want to
see if the structure itself is necessary for catalysis.
It is known that Sec is essential for the mammalian TR enzymes. However is has
also been demonstrated that other high eukaryotes, D.melanogaster and P.falcifarum,
utilized Cys and have comparable catalytic activities with the Sec containing counter
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parts. A second question I evaluate in the thesis is, why do some TRs utilize Sec while
other TRs are just as capable utilizing Cys?
Lastly, I intend to evaluate the answers to both of these questions to determine if
they are mutually exclusive or directly related.
It is my hypothesis, that for the enzymes containing a Cys-Cys dyad (CeTR2 and
DmTR), the presence of an eight-membered ring will be important to catalysis, while for
the Sec-containing mouse enzyme (mTR3) the ring structure will be of less importance.
In the active site of both TR and GR there is a conserved histidine residue that is essential
for activity (see Figure 3). During the catalytic cycle of GR, this histidine must donate a
proton to the first leaving group, GSH I. This part of the reaction is analogous with the
ring opening step of TR, where the Cys2 or Sec2 position of the dyad would act as the
first leaving group. I believe that for the Cys containing TRs, the ring structure is
essential for aligning the leaving group with this conserved histidine, to allow for proton
donation and stabilization of the leaving group thiolate. Conversely, the Sec residue of
the Sec class of TRs does not need to be protonated due to its low pKa leaving group, thus
making the eight-member ring less important.
Before I could evaluate these questions I wanted to characterize the mitochondrial
C. elegans TR (CeTR2) because its C-terminal sequence of GCCG is similar to the
mTR3 sequence of GCUG, which contains Sec and identical to mTR3 U to C mutant that
lacked significant activity (59). This sequence is unique compared to other examples of
TR from the literature that evolved using Cys in place of Sec such as the DmTR and
PfTR enzymes. Of these two examples, DmTR has a C-terminal sequence of SCCS,
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which contain the vicinal disulfide motif without the use of Sec. It has been proposed
that the flanking serine residues activate the Cys residues making them more reactive
(60). Of the other example, PfTR has a C-terminal sequence of GCGGGKCG (63). This
sequence lacks the flanking serine residue, but it also lacks the vicinal Cys motif with
insertion of four amino acids between the reactive redox center.

The cloning and

characterization of the CeTR2 enzyme as intein mediated fusion protein will allow for us
to examine it for its ability to reduce Trx.

This additional example of a Cys TR and

comparison of its activity with the other Cys TRs and the Sec TRs will validate or
disprove the proposal (mentioned earlier) put forth by Gromer in regards to the role of
flanking serine residues enhancing activity (60). Additionally, mutations that mimic the
DmTR motif, producing a CeTR2-SCCS construct will determine if the flanking serine
residues are necessary for activity or enhancing activity.
To evaluate the importance of the eight-membered ring structure in the catalysis
of TR, I propose to disrupt the WT conformation of the C-terminal ring. Mutagenesis
will be used to insert either one or two alanine residues between the vicinal Cys residues.
These insertions will enlarge the ring by three and six atoms producing eleven and
fourteen-membered rings, respectively. The effect of these insertions will be examined
by assaying these mutant enzyme constructs for TR activity to determine how important
the eight-membered ring is to catalysis, and if the larger membered, non-vicinal disulfide
rings can catalyze the reaction.
To evaluate why some TRs utilized Sec while others TRs utilize Cys, a peptide
complementation technique can be utilized in which truncated TRs lacking the C-
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terminal redox motif from both Sec and Cys TR classes, are assayed against peptide
substrates mimicking their C-terminus (Figure 4). The comparison of activity of WT
(Cys or Sec) cyclic peptides, which maintain specific conformations, with their
corresponding acyclic peptides, which have no rigid conformation because the peptide
bond between the vicinal Cys or Cys/Sec has been severed, should reveal details about
the importance of the ring structure. A similar comparison of activities between acyclic
peptides containing Sec or Cys in the penultimate position, will allow an evaluation of
the effect the leaving group has on the catalytic reaction. Also an acyclic mixed disulfide
of the peptide substrate conjugated to the highly reactive, low pKa TNB (5-thio-2nitrobenzoate) anion, acts as a Sec containing peptide analog. A final “switch” peptide,
in which the Sec and Cys residues have been swapped resulting in Cys in the penultimate
position, will be assayed. This peptide will result in information regarding, whether Sec
or Cys is the atom attacked by the interchange CysIC residue. Results regarding these
assays will allow us to propose a model for the mechanistic differences between the two
classes of high Mr TRs.
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Figure 1: Conserved enzymatic reaction scheme
A. Conserved enzymatic reaction scheme carried out by family of pyridine nucleotidedisulfide reductases. NADPH, which donates a hydride to an enzyme bound cofactor
(FAD), which in turn forms a charge-transfer complex with an enzyme disulfide and then
transfers the electrons to the target substrate disulfide. B. For the low Mr TR, the
substrate disulfide is Trx. C. For the high Mr TRs, the conserved enyzyme disulfide
reduces an addition enzyme disulfide redox center (from the opposing subunit of
homodimer, denoted by prime (′) symbol), which which reduces the Trx disulfide
substrate.
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Figure 2: Peptide Complementation
In this technique, the C-terminus that consists of the additional enzyme disulfide redox
center is removed, creating a truncated TR enzyme. This truncated TR can reduce,
oxidized disulfide peptides (see Figure 4) that mimic the C-terminus, allowing for the
kinetic investigation of this mechanism. Arrows denote flow of electrons through
enzyme.
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Figure 3: Conserved Active Site Histidine
A. Following reduction of the conserved enzyme disulfide, CysIC thiolate attacks the
disulfide substrate (oxidized glutathione for GR) or the additional enzyme disulfide (Cterminal vicinal disulfide of TR), resulting in the formation of a mixed disulfide between
CysIC and the release of the leaving group thiolate. The leaving group thiolate must be
protonated by the adjacent His residue, and can stably leave. Resolution of the enzyme
disulfide is initiated by attack of CysCT, and release of the second thiol. (Figure adapted
from Ref. (64)) B. Alignment of the tetrapeptide SCCS(ox) in the structure of TR from
Drosophila. The tetrapeptide structures were determined by NMR and placed in the
active site of TR in accordance to the position of Glutathione I (the interchange position)
in the GR structure (PDB 1GRA). Shown are the FAD cofactor (dark red) and the helical
loop of the conserved active site sequence CICVNVGCCT, which are components of chain
A. Also shown is Arg473’ from the B chain as well as His464’ and Glu469’, which are
analogous to His467’ and Glu472’ in GR. The oxidized C-terminal disulfide of the B
chain is reduced by the FAD-associated disulfide of the A chain during the enzymatic
cycle. The residues from TR are in gray, oxidized glutathione is in purple, the
tetrapeptide is in green. Cys57 (CysIC) of DmTR is in position for interchange with
glutathione I and the Cys489’ of the SCCS(ox) tetrapeptide, which is indicated by the
orange dashed line. Glutathione II is in position for protonation from His464’ as is
Cys490’ of the SCCS(ox) tetrapeptide as indicated by the red dashed line. Only the
cysteines for the SCCS(ox) peptide and GSSG are shown for simplicity. The prime
designation for residue numbers indicates the B chain of the TR homodimer. (Figure
adapted from Ref. (65))
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D

Figure 4: Peptide substrates constructed for this study.
A.) Typical WT cyclic octamer peptide, (X = S or Se atom of Cys or Sec, respectively),
that must reduced during TR’s catalytic cycle. B.) Acyclic octamer peptide. The peptide
bond between the vicinal Cys or Cys/Sec has been disconnected, thus preventing
formation of the cyclic structure. C.) Acyclic hexamer, Cys1 forms a mixed disulfide
with the thiol of the highly reactive TNB anion, referred to as Pep-TNB in the text. D.)
Cyclic “switch” mutant. The typical Cys1-Sec2 dyad of the eight-membered ring has been
“switched”, resulting in a Sec1-Cys2 dyad.
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Chapter 2
Characterization Of Mitochondrial Thioredoxin
Reductase From C.elegans
Introduction
The mitochondrial C. elegans thioredoxin reductase (CeTR2) contains the Cterminal motif of GCCG (62, 66), lacking the Sec residue so crucial to the mammalian
enzyme (59). It has recently been demonstrated that other higher eukaryotic species
contain TR lacking Sec (25, 60, 61, 67), but retain high catalytic activities. In the case of
the DmTR, where its C-terminal motif consists of sequence SCCS, it was postulated that
the flanking serine residues adjacent to the vicinal Cys’s aid in thiolate formation (60). It
is hypothesized that this serine activation, is the cause of the resulting high catalytic
activity.

To examine this hypothesis, here I report the cloning, purification and

enzymatic characterization of CeTR2. The recombinant CeTR2 was expressed as an
intein meditated fusion protein and characterized for TR activity. I also report mutations
to this C-terminal motif to SCCS and GCCS, to experimentally determine the effect
flanking serine residues would have on the catalytic rate of Trx reduction to evaluate if
they contribute to the rate as hypothesized by Gromer (60).

Methods
Mutagenesis and transformation.
The coding sequence for CeTR2 was amplified from an EST clone purchased
from Open Biosystems (clone ID ZK637.10) using PCR. The upstream primer had the
sequence 5′-AACAGACATATGTTCTCATCAAATAAATTTGATCTGATTG-3′, and
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the downstream primer was of sequence 5′-ACAGCCGCTCTTCAGCATCCACAGCAT
CCCTGAGTT-3′. The PCR was performed on a Perkin-Elmer GeneAmp PCR System
2400. The PCR (100 µL) contained 100 pg of template DNA (pDONR201, containing the
coding sequence), 50 pmol of each primer, 2 U of Vent DNA polymerase, 200 µM of
each dNTP, in a buffer containing 20 mM Tris–HCl, 10 mM (NH4)2SO4, 10 mM KCl, 2
mM MgSO4, and 0.1% Triton X-100, pH 8.8. The steps in the PCR were as follows: 96
°C (initial denaturation) for 2 min followed by 25 cycles of 96 °C (45 s), 55 °C, (30 s),
and 72 °C (3 min). The amplification reaction was monitored by analytical agarose gel
electrophoresis (staining with ethidium bromide). The DNA from the PCR was then
purified using the Qiagen QIAquick PCR Purification Kit. The PCR product was then
treated with restriction enzymes NdeI and SapI for 2 h at 37 °C in 50 mM potassium
acetate, 20 mM Tris–acetate, 10 mM magnesium acetate, 1 mM DTT, pH 7.9, in a total
volume of 50 µL. The digest was then purified using the Qiagen QIAquick PCR
Purification Kit and the purified DNA was used in a ligation reaction to subclone the
amplified gene into plasmid pTYB1. Two hundred nanograms of plasmid pTYB1 and
400 ng of PCR product were incubated with 400 U T4 DNA ligase at 16 °C overnight.
The ligase was inactivated by heating the reaction at 70 °C for 30 min. The ligation
reaction was then incubated at 37 °C with EcoRI for 2 h to enhance the amount of
positive clones because EcoRI will only cut plasmids that have not been ligated with the
PCR insert. The resulting plasmid (pCETR2) encodes a fusion protein consisting of
CeTR2, VMA1 intein, and a chitin-binding domain. Escherichia coli DH5a cells made
competent by CaCl2 were transformed with 20 ng of pCETR2 (68). The cells were plated
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on LB-agar containing ampicillin (200 µg/mL). Positive clones were screened by
restriction analysis using HindIII and NdeI, and analyzed by analytical agarose gel
electrophoresis. Several positive clones were then selected for DNA sequencing to verify
the wild-type coding sequence. All sequencing was performed by the University of
Vermont DNA Sequencing Facility using an ABI 3100-Avant Genetic Analyzer.
Two mutant C. elegans TRs were also constructed using PCR using the same
conditions

listed

above

except

that

downstream

primer

5’-

ACAGCCGCTCTTCAGCATGAACAGCATCCCTGAGTTCTT-3’ was used to create a
mutant with C-terminal sequence GCCS (abbreviated as TR-GCCS) and downstream
primer 5’-ACAGCCGCTCTTCAGCATGA ACAGCATGACTGAGTTCTT-3’ to create
a mutant with C-terminal sequence of SCCS (abbreviated as TR-SCCS).
Protein production.
Escherichia coli ER2566 cells were used for production of recombinant wild-type
(WT) and mutant CeTR2 enzymes. The cells were transformed with plasmid pCETR2,
plated on LB-ampicillin plates containing 200 µg/mL ampicillin, and incubated at 37 °C
overnight. A single colony isolated from the LB/ampicillin plate was used to grow a 100
mL inoculum culture of LB (200 µg/mL ampicillin). This culture was incubated
overnight at 37 °C with shaking. Ten milliliters of inoculum culture was added to each of
6 x 1 L baffled Pyrex Fernbach flasks of TB media containing 200 µg/mL ampicillin. The
cells were incubated at 37 °C with shaking (100 rpm) until the OD600 nm reached 1.0.
The cells were then chilled on ice until the temperature decreases to 20 °C and induced
by adding IPTG to a to final concentration of 0.5 mM followed by incubation at 20 °C
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overnight with shaking (100 rpm). The cells were harvested by centrifugation in a
Beckman J21B centrifuge (JA-14 rotor) at 7000g at 4 °C for 10 min and then stored at 20 °C.
Enzyme purification.
The frozen cell pellets were thawed on ice and resuspended in 200 mL of 50 mM
MOPS, 150 mM NaCl, pH 7.0, until homogeneous. The homogenate was sonicated with
a Branson 350 Sonifier (Danbury, CT) on ice to break open the cells. The sample was
then centrifuged with a Beckman J21B centrifuge (JA-14 rotor) at 7000g for 90 min at 4
°C. The supernatant was gravity loaded onto a 60 mL column of chitin–agarose with a
flow rate of 0.5–1.0 mL/min. The column was washed with 50 mM MOPS, 150 mM
NaCl, pH 7.0, until the absorbance at 280 nm reached 0.05. This was followed by a 1 L
wash of 50 mM MOPS, 500 mM NaCl, pH 7.0. As a final step, the column was then
washed with 1 volume of column buffer that contained 140 mM βME (since the fusion
protein was resistant to cleavage by βME, I found that a wash with this thiol greatly
improved the purity of the protein in this step). The enzyme was then liberated from the
intein-fusion protein by incubation of the chitin resin with column buffer (50 mM MOPS,
500 mM NaCl, pH 8.0) containing a small molecule thiol. The thiol-cleavage fractions
were concentrated by ultrafiltration using an Amicon Ultra 30000 MWCO (Millipore)
concentrator to a final volume of 1–2 mL. The concentrated protein was gravity loaded
onto a gel filtration column (S200, Pharmacia) of dimensions 3.8 cm x 97 cm. The gel
filtration column was equilibrated with 50 mM MOPS, 500 mM NaCl, pH 7.0. Fractions
were collected (3 mL each) and then analyzed by UV–Vis spectrophotometry at 280 and
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460 nm. Peak fractions were assayed for DTNB reductase activity and analyzed by SDS–
PAGE (12% gels). Peak fractions exhibiting DTNB reductase activity were pooled and
concentrated by ultrafiltration. The protein concentration was determined using an
extinction coefficient of 22.6 mM-1 cm-1 at 460 nm. The concentrated protein was then
stored at 4 °C until needed. The optimal thiol for cleavage was determined by a cleavage
assay as described in the next section.
Optimization of thiol-mediated cleavage.
Initially, I found the fusion protein to be resistant to cleavage using 70 mM βME
as a thiol at pH values ranging from 7 to 8. In order to find the best conditions for thiol
mediated cleavage, I explored a variety of thiols and pH values to liberate our target
protein (CeTR2) from the chitin–agarose. Four different batches of chitin resin (6 mL
slurry) were treated with 15 mL buffer (50 mM MOPS, 500 mM NaCl, pH 7.0)
containing

either

140

mM

βmercaptoethanol

(βME),

140

mM

N-

methylmercaptoacetamide (NMA), 140 mM dithiothreitol (DTT), or 140 mM
mercaptoethanesulfonic acid (sodium salt) (MESNA), and incubated at room temperature
overnight while mixing using a platform rocker (the pH of the slurry was adjusted to 7.0
after the addition of thiol). A control reaction was done in which buffer was added to the
slurry that did not contain thiol. The resin was then filtered and then washed with column
buffer that did not contain thiol. The combined effluent was concentrated by
ultrafiltration and the samples were then analyzed by 12% SDS–PAGE electrophoresis.
Enzyme activity assays.
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The activity of the recombinant proteins was tested for their ability to reduce
DTNB (5,5’-dithiobis(2-nitrobenzoate)) by monitoring the increase in absorbance at 412
nm (69). The assay contained 4 nM enzyme, 100 mM potassium phosphate buffer, pH
7.0, 10 mM EDTA, 0.2 mM NADPH, and DTNB (0–5 mM) in an assay volume of 0.5
mL. Thioredoxin reductase activity was measured using E. coli Trx as substrate, by
monitoring the consumption of NADPH by measuring the decrease in absorbance at 340
nm as previously described (70). Briefly, assay mixtures contained 50 mM potassium
phosphate, pH 7.0, 1 mM EDTA, 0.15 mM NADPH, 0.16 mM bovine insulin, and E. coli
Trx (0–420 µM) in a volume of 0.5 mL. The TR concentration was 40 nM for this assay.
The data were fit to a straight line over a 2 min range on the Varian-Cary 50
spectrophotometer to calculate the change in absorbance/min.
Activity towards other substrates.
WT enzyme was tested for its ability to reduce selenocystine, hydrogen peroxide,
and bovine pancreatic insulin. These assays were carried out as previously described with
slight modification (70). The assay conditions were: 100 mM potassium phosphate, pH
7.0, 10 mM EDTA, 0.2 mM NADPH, and 200 nM WT enzyme, in a final volume of 0.5
mL for assays using selenocystine or H2O2 as substrates. The assay for bovine pancreatic
insulin was tested under the following conditions: 50 mM potassium phosphate, pH 7.0, 1
mM EDTA, 0.15 mM NADPH, and 400 nM WT enzyme in a 0.5 mL assay. Activity was
measured by following the decrease in absorbance at 340 nm, indicating consumption of
NADPH. The concentration of selenocystine in the assay was 85 µM. Hydrogen
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peroxidase activity was measured using concentrations of H2O2 varying from 0 to 500
µM. Insulin concentrations were in the range of 0.2–1 mM.
pH rate profiles.
WT and mutant enzymes were tested for their ability to reduce E. coli Trx at
varying pH. The assay was similar to the assay described above with slight modification.
In brief, the assay buffer contained 200 mM each of sodium acetate, sodium phosphate
(monobasic), sodium phosphate (dibasic), and boric acid. The pH of the buffer was
adjusted by 0.5 pH units with HCl or NaOH to give the desired pH value. Insulin was
omitted due to precipitation at low pH and each assay reaction contained 500 µM E. coli
Trx, 1 mM EDTA, 0.15 mM NADPH, and 60 nM enzyme in a final volume of 0.5 mL.

Results and Discussion
Cloning and Production of Recombinant Enzymes in E. coli.
Sequence analysis of the amplified PCR product indicated that the cloned DNA
was identical to that of Genbank accession # Z11115, which was previously identified as
the mitochondrial TR from C. elegans (62). For production as a recombinant protein in
E. coli, I removed the mitochondrial signaling sequence (MLLSTFKRHLPIRRL) and
fused the enzyme to an intein-chitin binding domain that allows for affinity purification.
Figure 5 details my strategy for isolating the recombinant enzyme. The cell extract was
loaded onto a chitin-agarose column and after extensive washing with column buffer, the
C.e. TR2 enzyme was liberated by thiol-mediated cleavage. The liberated protein was
eluted from the column with its C-terminus in the form of a thioester. This thioester
group hydrolyzes over several days to produce the free carboxylate, typical of C-termini
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of proteins(71) . The chitin-agarose column afforded a high level of purification of the
enzyme as shown by the 12% SDS-PAGE gel in Figure 6A. The apparent MW of C.e.
TR2 is ~55 kDa, typical of high molecular weight thioredoxin reductases (21). The
enzyme was then purified to greater than 95% homogeneity (judged by SDS-PAGE) after
S200 size-exclusion chromatography (data not shown).

The intein-fusion strategy

allowed us to purify the enzyme in a two-step process, and also allows us to take
advantage of the protein engineering utility of inteins for future experiments (72). The
intein strategy has proven useful to us in the past, however in the case of C.e. TR2, this
strategy proved to be challenging as cleavage from the intein through the use of a thiol
proved difficult. Figure 6B shows the cleavage of mouse TR2 from an intein fusion
protein using different thiols. The thiols βME, NMA, and DTT all cleaved with similar
efficiency, while MESNA cleaved with the least efficiency. Initially I tried to cleave the
C.e. TR2-intein fusion protein with βME, which resulted in little or no cleavage. The
results of our thiol cleavage assay in Figure 6A demonstrate the superiority of NMA as a
cleavage thiol. DTT and βME did not cleave the construct to any significant extent at
either pH 7.0 or pH 8.0. MESNA (data not shown) also demonstrated an inability to
cleave the fusion protein. However, as can be seen in Figure 6A, NMA cleaved the
fusion protein to a significant extent at pH 7.0 and allowed us to use the intein strategy as
a method for isolating the recombinant enzyme with a final yield of 2 mg/L of cell
culture. The purified WT and mutant enzymes absorbance spectra were scanned from
200 to 600 nm (data not shown), with characteristic maxima at 370 nm and 460 nm for
the flavin-bound cofactor present.
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Thioredoxin Reductase Activity.
The thioredoxin reductase activity of C.e. TR2 was determined using E. coli Trx
as substrate. E. coli Trx has been used as a standard to measure the thioredoxin reductase
activity of many different types of TR’s, however it has been shown that TR’s from
different species prefer their cognate thioredoxin as a substrate, and the preference for the
cognate thioredoxin molecule can vary greatly between species(25).
This activity was measured using a well-developed assay as described by
Holmgren (70). The results of the assay containing NADPH, bovine insulin, and E. coli
Trx in 50 mM potassium phosphate buffer for WT and mutant C.e. TR’s are shown in
Figure 7 as a Michaelis-Menten plot and the kinetic data is summarized in Table 1. The
results show that the WT enzyme has high activity towards E. coli Trx as measured by its
high value of kcat (610 min-1). However, the WT enzyme also has a high Km value (610
µM) towards E. coli Trx, indicating that the non-cognate Trx is not the optimal substrate
for the enzyme. It is likely that the C.e. TR2 would bind its cognate Trx with much
higher affinity resulting in a lower Km value. This result is similar to the results of the TR
from Plasmodium falciparum (P.f.), which also has high activity towards E. coli Trx, but
also displays a high Km value (67). When the P.f. TR is assayed using its own cognate
Trx, the kcat value is similar to the kcat value when E. coli Trx is the substrate, but the Km
value for the cognate Trx is much lower (Table 2). The high value of kcat towards E. coli
Trx does indicate that like the TR’s from Drosophila melanogaster and Plasmodium
falciparum, the reduction of the catalytic disulfide bond of Trx does not require selenium,
and furthermore that the enzymes containing an active-site thiolate nucleophile are
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capable of achieving catalytic rates comparable to the mammalian enzymes which
contain Sec.
The WT enzyme has unusual kinetic properties at low substrate concentration (0 –
30 µM). When measuring the absorbance at 340 nm during the assay, the absorbance
should decrease indicating consumption of NADPH and turnover of substrate. However
at low substrate concentration, the absorbance was observed to increase. This either
indicates that the enzyme has NADPH oxidase activity at low substrate concentration, or
the enzyme exhibits cooperativity. Alternatively, this result may be an artifact of using a
non-cognate Trx as substrate. Neither mutant enzyme displayed this property.
The mitochondrial TR from C. elegans (C.e. TR2) is of interest because of the
proposal by Arnér and coworkers that D.m. TR can achieve high catalytic activity
without the need for Sec because of the presence of flanking serine residues in the Cterminal tetrapeptide SCCS redox center of the enzyme(60). These serine residues take
the place of flanking glycine residues in the mammalian C-terminal tetrapeptide motif of
GCUG. It was proposed that the serine residues act as general bases with the assistance
of a nearby histidine residue to deprotonate the Cys residues during the catalytic cycle of
the enzyme. C.e. TR2 is a naturally occurring Cys-containing TR (Cys replaces Sec in
the active site) that has a flanking glycine residue on each side of the vicinal Cys motif.
Thus in the case of C.e. TR2, there is no requirement for flanking serine residues to assist
in proton abstraction and the enzyme can achieve high activity in the absence of Sec.
The mechanism of D.m. TR may require the presence of flanking serine residues to
achieve catalysis, but this is certainly not the case for the C.e. TR2.
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I have also constructed several mutants to further explore the hypothesis put forth
by Arnér and coworkers that flanking serine residues are essential for TR’s with vicinal
Cys residues(60).

In D.m. TR, it was shown that the C-terminal serine was more

important to catalysis since mutation of this residue to glycine affected the catalytic
activity the most. When I changed the C-terminal glycine residue of C.e. TR2 to serine I
did not observe an increase in activity as might be expected if the presence of a serine in
this motif could function to deprotonate the C-terminal Cys residue as in the Arnér
proposal. In fact, the activity of the enzyme decreased 8-fold in kcat, however, this mutant
did show better binding of the substrate as Km decreased nearly 2-fold. Thus this residue
may be important for substrate binding and further differences in Km may be observed
with this mutant when comparing E. coli Trx to the cognate Trx from C. elegans.
However, the mitochondrial Trx from C. elegans has not been cloned and as far as I
know is unavailable. This is an area for future work. When both flanking glycine
residues are mutated to serine (the opposite experiment to that in ref. (60)), the activity is
3 fold lower in kcat and has a 2.5-fold lower Km. The results show that similar to the
proposal of Arnér and coworkers, the C-terminal flanking residue seems to be more
important for catalysis than the N-terminal flanking residue in C.e. TR2.
DTNB reductase activity.
DTNB has been widely used as a substrate for thioredoxin reductases as the
disulfide bond of this substrate is highly reactive and this provides a convenient method
for assaying the enzyme during purification. The catalytic constants using DTNB are
usually reported as a means of comparing the activity of different TR’s towards a
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common substrate(59). The Michaelis-Menten plot for C.e. TR2 using DTNB as a
substrate is shown in Figure 8. The enzyme has a kcat of 134 min-1 and a Km of 0.42 mM.
This compares to a kcat of 2,100 min-1 and a Km of 100 mM for the mammalian Seccontaining enzyme (73). The kcat of the C.e. TR2 for DTNB is similar to that of the
mammalian U498C mutant (Sec to Cys mutation) (220 s-1) (73). Sometimes a specific
activity for DTNB at a concentration of 5 mM is reported in the literature (59). For
example, calf liver TR has a specific activity of 1,333 mol NADPH/min/mol TR at 5 mM
DTNB, while the corresponding value for C.e. TR2 is 130. This most likely reflects the
poorer nucleophilicity of the active site thiolate of C.e. TR2 compared to the selenolate
for the mammalian enzyme.
C.e. TR2 was also tested for its ability to reduce several other substrates (Table
3). The enzyme showed no detectable hydrogen peroxidase activity and no ability to
reduce disulfide bonds of peptides such as in insulin. The lack of hydrogen peroxidase
activity is consistent with previous reports of the requirement for selenium to catalyze
this reaction and reflects the poorer nucleophilicity towards peroxide bonds by sulfur in
comparison to selenium (74). The enzyme was able to utilize selenocystine as a substrate
and I report a specific activity of 29 min-1 using 85 µM selenocystine.
pH Rate Profile.
WT and mutant enzymes were tested for their ability to reduce E. coli Trx at
varying pH. The WT enzyme was found to have a pH optimum centered near pH 8.0
(Figure 9). Mutant enzymes containing altered C-terminal tetrapeptides (GCCS and
SCCS) also showed a pH optimum near 8.0, but the mutant profiles are somewhat
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broader than the WT enzyme. The mammalian Sec-containing enzyme shows a pH
optimum near 7.0, while the pH optimum is shifted between 8-10 for the mammalian
U498C mutant (59). The C.e. TR2 enzyme, like the mammalian U498C mutant also
shows a pH optimum shifted towards 8.0, but the profile is narrower compared to the
Cys-containing mammalian mutant. C.e. TR2 likely evolved to utilize the nucelophilicity
of an active-site thiolate, potentially through the use of a general base.
The mitochondrial TR of the nematode C. elegans has evolved down a different
path than that of the mammalian mitochondrial enzyme. While the cytosolic C. elegans
TR1 contains Sec, its mitochondrial counterpart does not. It is not known why C. elegans
has evolved to contain the entire Sec decoding apparatus for one Sec-containing enzyme
(75). One possibility for the mitochondrial C.e. TR is that it originally contained Sec, but
was lost through evolution and was replaced with Cys. It has been proposed that the
occurrence of Sec in proteins is the result of a recent evolutionary event (76) and that the
presence of Sec in TR enables the enzyme to have additional biological roles inside the
cell other than the reduction of Trx (77). Thus, the function of the mitochondrial TR
from C. elegans may be limited to the reducing the catalytic disulfide bond of Trx
because the redox-sensing function of TR may be performed by other proteins in this
organelle of C. elegans.

Conclusions
In conclusion, the C.e. TR2 enzyme containing Cys in place of Sec has high
catalytic activity towards E. coli Trx, as has been observed for the Cys-containing TR of
D. melanogaster (25). The C.e. TR2 enzyme must use a mechanism that is slightly

31

different from that of the D.m. TR since no requirement for flanking serine residues is
observed.
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Table 1: Kinetic Constants for WT and Mutant Enzymes using E. coli Trx as
Substrate.
Enzyme
kcat (min-1)
kcat / Km (min-1•M-1)
Km (µM)
C.e. TR-GCCG (WT)
1.0 x106
610 ± 36
610 ± 60
C.e. TR-GCCS
2.4 x105
318 ± 25
77 ± 3
C.e. TR-SCCS
9.0 x105
242 ± 33
219 ± 14
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Table 2: Comparison of Kinetic Constants of TR’s from Various Species.
-1
Enzyme
Substrate
kcat / Km (min-1•M-1)
Km (µM) kcat (min )
a
rTR-GCUG
H. sapiens Trx
3.3
2500
7.58 x108
rTR-GCCGa
H. sapiens Trx
0.4
14.3
3.58 x107
C.e. TR-GCCG
E. coli Trx
610
610
1 x106
P.f. TR-GCGGGKCGb P.f. Trx
2.1
1674
7.97 x108
b
P.f. TR-GCGGGKCG E. coli Trx
500
1688
3.38 x106
D. m. TR-SCCSc
D.m. Trx
7.1
1320
1.86 x108
d
A.g TR-TCCS
A.g. Trx
8.5
924
1.13 x108
a
Taken from ref.(59).
b
Taken from ref. (67).
c
Taken from ref. (25).
d
Taken from ref. (61).
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Table 3: Activity of C. elegans TR2 vs. Various Substrates.
Substrate
Activity (mol NADPH/min/mol of TR)
DTNB
130
29
Selenocystine ( 85 µM)
Hydrogen peroxide
No activity
Insulin
No activity
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Figure 5: Fusion protein mechanism for affinity purification
The target protein, C.e. TR, was fused at its carboxy terminus with an engineered intein.
The construct also has a chitin-binding domain (CBD) at the C-terminus, which allows
for affinity purification with chitin-agarose. The CBD is a small peptide that has high
affinity for chitin-agarose, and this resin provides a high level of purification of the
fusion protein. The Cys residue (of the intein) at the TR-intein junction, undergoes a N-S
acyl shift resulting in the formation of a thioester bond at the TR-intein junction.
Addition of a small thiol (NMA) mediates cleavage of TR from the intein, which remains
bound to the chitin resin through the CBD. The liberated thioester tagged protein then
undergoes hydrolysis yielding a native carboxy terminus.

36

A.
C.

B.

Figure 6: Thiol mediated cleavage efficiency of different small molecule thiols.
In (A), C.e. TR2 is cleaved with 140 mM thiol at pH 7.0. Lane 1: ΜWM. Lane 2: Fresh
chitin resin without protein that has been treated with a 1% SDS solution as a control.
Lane 3: The column wash (buffer) after fresh chitin resin has been loaded with protein
extract. Lane 4: 1% SDS wash from a chitin column loaded with protein extract. Lane 5:
βME wash of chitin column. Lane 6: 1% SDS wash of column following βME wash.
Lane 7: DTT wash of chitin column. Lane 8: 1% SDS wash of column following DTT
wash. Lane 9: NMA wash of chitin column. Lane 10: 1% SDS wash of column
following NMA wash. The liberated C.e. TR2 is indicated by the arrow showing the
band with an apparent MW of 55 kDa. In (B), mouse TR3 is produced as an intein fusion
and cleaved with different thiols (50 mM) at pH 7.0. Lane 1: βME. Lane 2: ΜWM. Lane
3: NMA. Lane 4: DTT. Lane 5: MESNA. In (B) NMA, DTT, and βME all cleave with
comparable efficiencies, with MESNA being the least efficient cleavage thiol. In (A) the
superiority of NMA as a cleavage thiol is evident. In (C), the structures of each thiol
(from top top to bottom: βME, NMA, DTT, and MESNA), along with their
corresponding pKa values are shown (78).
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Figure 7: Michaelis-Menten plot of WT and mutant enzymes using thioredoxin as
substrate.
Purified WT and mutant C. elegans TR’s were assayed for their ability to reduce E. coli
Trx. The activity was monitored by consumption of NADPH via a decrease in
absorbance at 340 nm. Reaction mixtures contained 50 mM potassium phosphate pH 7.0,
1 mM EDTA, 150 µM NADPH, 160 µM bovine pancreatic insulin, 1-450 µM E. coli Trx
and 40 nM enzyme. The WT enzyme is represented by the closed circles (TR-GCCG),
open squares represent TR-GCCS, and closed diamonds represent TR-SCCS
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Figure 8: Michaelis-Menten plot of WT CeTR2 using DTNB as substrate.
The assay contained 100 mM potassium phosphate, pH 7.0, 10 mM EDTA, 200 µM
NADPH, 4 nM enzyme, and 0-5.0 mM DTNB. Reactions were monitored over 2 min for
an increase in absorbance at 412 nm indicating reduction of DTNB.
Activity is
expressed as mol of NADPH consumed/min/mol TR.
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Figure 9: Activities of WT and mutant CeTR2 as a function of pH.
The thioredoxin reductase activity of WT and mutant enzymes was measured in buffers
of varying pH. The activity was measured in 0.5 pH unit increments and is expressed as
a percent of the maximal activity. Reaction mixtures contained 200 mM each of
potassium phosphate (monobasic), potassium phosphate (dibasic), sodium acetate, and
boric acid along with 1 mM EDTA, 150 µM NADPH, 60 nM enzyme, and 500 µM E.
coli Trx. The WT enzyme is represented by the closed circles (TR-GCCG), open squares
represent TR-GCCS, and closed diamonds represent TR-SCCS.
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Chapter 3
C-Terminal Mutagenesis Studies of
Mitochondrial Thioredoxin Reductase

C.

elegans

Introduction
As discussed in Chapter 1, the C-terminal vicinal Cys residues form a strained
eight-membered ring. Since there are several examples of Mr TR that have similar
functional catalytic activities, compared to the mammalian Sec containing TRs, I want to
evaluate the role of this ring in catalysis.
Since the eight-membered ring motif is rare in nature, I wanted to test the effect of
changing the conformation of the ring by making it larger. The use of PCR mutagenesis
was performed to insert either one or two alanine residues between the vicinal Cys
residues. This resulted in eleven and fourteen-membered rings (Error! Reference source
not found.).

These constructs were assayed for DTNB, and Trx reductase activity.

Additionally, I examined their pH dependence on the reduction of E.coli Trx.

Methods
Cloning of His-Tagged CeTR2.
Plasmid pCeTR2 (26) was used as a template to clone the CeTR2 gene into
plasmid pET45b(+) (Novagen) using an upstream primer containing a “hexaHis-tag”. For
this construct, an upstream primer of sequence 5′-ACAGCCCCGGATCCCTTCTCATC
AAATAAATTTGATCTG-3′

was

used

with

downstream

primer,

ACAGCCAAGCTTGTCGACTCATCCACAGCATCCCTGAGTTCTTGG-3′
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in

5′the

amplification process to produce the WT enzyme with C-terminal sequence Gly-CysCys-Gly.

C-terminal

mutants

were

produced

using

downstream primers

5′-

ACAGCCAAGCTTGTCGACTCATCCACATGCGCATCCCTGAGTTCTTGG-3′ (GlyCys-Ala-Cys-Gly

mutant),

and

5′-ACAGCCAAGCTTGTCGACTCATCC

ACATGCTGCGCATCCCTGAGTTCTTGG-3′ (Gly-Cys-Ala-Ala-Cys-Gly mutant). The
resulting plasmids (pHisCeTR2) encode a protein with a N-terminal hexa-histidine tag
followed by an enterokinase cleavage site and the CeTR2 protein.
The PCR reaction mixtures contained 100 pg template DNA, 50 pmol of each
primer, 2 units of Vent DNA Polymerase, 2 mM magnesium chloride, in a volume of 100
µL. Each PCR was performed on a GeneAmp PCR System 2400 from Perkin Elmer Life
Sciences, Inc. (Boston, MA) using 25 cycles with the following parameters: 96 oC for 45
sec, 50 oC for 30 sec, and 72 oC for 180 sec. The product was analyzed by analytical
agarose gel electrophoresis and then purified using the QIAquick Purification Kit from
Qiagen (Valencia, CA).
The PCR product and pET45b(+) plasmid were then treated with restriction
enzymes Bam HI and Sal I for 2 h at 37°C. Digests were purified using the Qiagen
QIAquick PCR purification kit. Ligation reactions contained 200 ng of plasmid and 400
ng of PCR product and were incubated at 16 oC for 16 h using T4 DNA ligase. Following
heat in activation of T4 DNA ligase for 15 min at 70 oC, the ligation reaction was then
incubated at 37 °C with 5U Asc I for 2 h to enhance the amount of positive clones as Asc
I will only cut plasmids that have not been ligated with the PCR insert. E. coli DH5α
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cells were made competent via the Inoue method (79) and then transformed with 1 µL of
purified, background digested, DNA. DNA from isolated colonies were purified using
QIAprep Spin Minprep Kit (Qiagen) and screened by restriction analysis using Bam HI
and Sal I, analyzed by analytical 0.8% agarose gel electrophoresis, and positive clones
were verified by sequencing of the DNA coding region at the DNA Analysis Core
Facility, Vermont Cancer Center, University of Vermont.
Purification of WT and Mutant CeTR2 Enzymes.
For expression of recombinant WT CeTR2 and mutant enzymes, E. coli ER2566
cells were used. The cells were transformed with the plasmid, plated on LB-ampicillin
plates containing 200 µg/mL ampicillin, and incubated at 37 °C overnight. A single
colony was used to grow a 100 mL inoculum culture of LB (200 µg/mL ampicillin). This
culture was incubated overnight at 37 °C with shaking. An inoculum culture of 10 mL
was added to a 1 L baffled Pyrex Fernbach flask containing TB media (12 g/L tryptone,
24 g/L yeast extract, 4 mL/L glycerol, 16 mM potassium phosphate monobasic and 72
mM potassium phosphate dibasic at pH 7.0 and supplemented with 20 mg/L each of
niacinamide, pyridoxine, and riboflavin) containing 200 µg/mL ampicillin. The cells
were incubated at 37 °C with shaking (100 rpm) until the O.D. at 600 nm reached 1.0.
The cells were then chilled on ice until the temperature decreased to 20 °C and then
induced by adding IPTG to a to final concentration of 0.5 mM. The induced cells were
incubated at 20 °C overnight with shaking (100 rpm). The cells were harvested by
centrifugation and stored at –20 °C.
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The frozen cell pellets were thawed on ice and homogenized in 100 mL of 50 mM
sodium phosphate, 500 mM NaCl, 10 mM imidazole, 10% glycerol, 20 mM βME, pH
8.0, until homogeneous. Lysozyme was added to the homogenate at a concentration of 1
mg/mL and allowed to stir at 4 °C for 1 h. The homogenate was then briefly sonicated (5
x 30 sec). The sample was then centrifuged with a Beckman J21B centrifuge (JA-14
rotor) at 7000 x g for 90 min at 4 °C. The supernatant was gravity loaded onto a 5 mL
column of Ni-NTA resin with a flow rate of 0.5–1.0 mL/min. The column was washed
with the buffer until the absorbance at 280 nm reached 0.05. This was followed by a wash
with buffer containing 20 mM imidazole to eliminate nonspecific protein binding after
which the protein was eluted in a buffer containing 250 mM imidazole
The protein was dialyzed against modified TE buffer (10 mM Tris, 1 mM EDTA,
10 mM NaCl, pH 8.0, 2 x 4L). The dialyzed protein was then reduced by addition of 20
mM βME and then loaded on to a 2′,5′-ADP Sepharose column (20 mL, Amersham)
equilibrated with 10 mM Tris, 1 mM EDTA, 10 mM NaCl, 20 mM βME, pH 8.0 and
washed until the A280 was below 0.05. Protein was eluted in buffer containing 3 M NaCl
and analyzed by 12% SDS-PAGE. Fractions were pooled and concentrated by
ultrafiltration using an Amicon Ultra 30,000 molecular weight cut off (MWCO)
(Millipore) concentrator to a final volume of 1–2 mL. The concentrated protein was
gravity loaded onto a Sephacryl S-200 gel filtration column (Pharmacia) of dimensions
3.8 cm x 97 cm. The column was equilibrated with 50 mM potassium phosphate, 300
mM NaCl, and 1 mM EDTA at pH 8.0. Fractions were collected (4 mL each) and then
analyzed by UV–Vis spectrophotometry at 280 and 460 nm and examined for purity by
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12 % SDS–PAGE. Fractions exhibiting the 55 kD band were pooled and concentrated by
ultrafiltration.
Production of Thioredoxin.
The clone containing the gene for TrxA from E. coli was a gift from Ronald T.
Raines (80) and was produced as previously described (81). E. coli BL21(DE3) cells
made competent with CaCl2 and transformed with 50 ng of DNA and plated onto LB agar
supplemented with 200 µg/mL ampicillin. Single colonies were used to inoculate 100 mL
ampicillin-containing LB media and allowed to shake overnight at 37 oC.
Six liters of LB media (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl)
supplemented with 200 µg/mL ampicillin was inoculated with 10 mL (each liter) of
inoculum culture and grown to an O.D. of 0.6 at 600 nm while shaking at 37 oC in a
C25KC shaker incubator (New Brunswick Scientific). The cells were induced for 3 h at
37 oC with 0.5 mM IPTG, and then harvested by a 10 min centrifugation at 10,000 rpm in
a JA-14 rotor using a Model J-21B centrifuge from Beckman. The resulting cell pellets
were frozen at –20 oC. The cells were then thawed on ice, homogenized in 20 mM Tris,
pH 8.4 containing 1 mM EDTA, and lysed by probe sonication using a Branson Sonifier.
The lysate was centrifuged as described above for 90 min and the resulting supernatant
was loaded onto a 70 mL column of DEAE sephacel (Sigma-Aldrich) equilibrated with
the lysis buffer. After loading, the column was washed with buffer until the A280 of the
effluent was 0.05. The sample was eluted using two 400 mL gradients containing NaCl (0
mM to 100 mM and 100 mM to 250 mM). Fractions were collected (3 mL) and evaluated
by absorbance at 280 nm and further analyzed by 15% SDS-PAGE. Fractions containing
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Trx were pooled and then adjusted to 60% ammonium sulfate saturation and centrifuged
as above for 60 min. The pellet was solubilized in a minimal volume of 20 mM Tris pH
8.4, 250 mM NaCl, 1 mM EDTA.
A 2 mL sample was loaded onto a Sephacryl S-100 HR, 98 cm x 3.3 cm, gel
filtration

column

from

Pharmacia-Amersham

Biosciences

(Uppsala,

Sweden)

equilibrated with sample buffer. Collected fractions (1 mL) were evaluated by absorbance
at 280 nm and SDS-PAGE. The fractions containing Trx were pooled, concentrated using
an Amicon Ultra with 5000 MWCO from Millipore. Purity was > 95% as judged by 15%
SDS-PAGE. The Trx concentration was calculated using the extinction coefficient at 280
nm of 13,700 M-1•cm-1 (82).
Enzymatic Characterization of Thioredoxin Reductase.
The TR mutants were assayed for activity towards DTNB, and Trx, as described
by Arner (70). All assays were performed on a Cary 50 UV/VIS spectrophotometer from
Varian (Walnut Creek, CA) at 25 oC, pH 7.0, and were initiated by addition of enzyme.
Spectral properties of purified TR were evaluated at 275 nm, 370 nm, 460 nm and the
concentration of homodimeric TR was determined using the flavin extinction coefficient
at 460nm of 22.6 mM-1•cm-1 (70). Activity was monitored over 2 min with Vo determined
from the linear fit. Plots of Vo/ET vs. substrate concentration were fit by the MichaelisMenten equation using KaleidaGraph 4.02 from Synergy Software (Reading, PA) and
activities reported as moles of NADPH consumed per min per mole of TR dimer.
The DTNB assay contained 0.2 mM NADPH and 10 mM EDTA in 100 mM
potassium phosphate. For each concentration of DTNB, activity was corrected for
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background by addition of buffer only. Activity was measured by the increase in
absorbance at 412 nm, calculated using the extinction coefficient for TNB-S-(5-thio-2nitrobenzoate, 13.6 mM-1•cm-1), and divided by two to account for the production of 2
TNB-S- per NADPH consumed. The concentration of CeTR2 was 4 nM.
The Trx assay contained 0.15 mM NADPH, 1 mM EDTA, and 10 mg/mL insulin
in 50 mM potassium phosphate in a volume of 500 µL. Activity was background
corrected for each concentration of Trx by addition of buffer only as well as with enzyme
in the absence of substrate. Activity was measured by the decrease in absorbance at 340
nm for the consumption of NADPH and calculated using the extinction coefficient of
6200 M-1•cm-1. The concentration of WT CeTR2 in the assay was 40 nM. The
concentration of each mutant TR was adjusted to achieve a similar change in absorbance
at 340 nm as that of their respective WT TR. The single and double alanine insertion
mutants displayed poor Trx activity and required 1600nM and 800nM of homodimeric
TR in the assay, respectively.
pH Optima of Trx Reduction.
Activity towards Trx was tested as a function of pH for each construct. Due to
the insolubility of insulin below pH 7.0, each assay utilized 500 µM Trx, which is
approximately ten times greater than the estimated Km. To avoid differences in ionic
strength, each assay contained buffer with a final concentration of 30 mM citrate/ 30 mM
Tris/ 30 mM phosphate adjusted from pH 5.5 to 10.0. The concentration of TR in the
assay was the same as used for the Trx Michaelis-Menten profile. Each assay contained
0.15 mM NADPH and 1 mM EDTA. The activity was measured at 340nm and
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background corrected. The data were collected in duplicate and then normalized to the
percent of maximal activity for each given mutant and plotted as percent activity vs. pH.

Results and Discussion
Thioredoxin Reductase Activity for CeTR.
Increasing ring size of the Cys-Cys dyad by inserting alanine residues resulted in
a 145 fold decrease in kcat for the single insertion and 90 fold decrease for the double
insertion respectively, while the Km was little affected compared to WT CeTR2 (Table 4,
Figure 11). Similar results are observed for DmTR, which also had a greatly reduced
activity 150 to 300 fold loss in kcat, compared to WT DmTR (Table 5). Similar results
were not observed with mTR3, where increasing the ring size of the Cys-Sec dyad by
inserting alanine residues had only a modest effect on activity (4-6 fold lower) (Table 6).
These results indicate that the non-selenium enzymes have a greater dependence on a
vicinal disulfide than does the mammalian enzyme for a vicinal selenylsulfide.
Comparison of DTNB Reductase Activities.
The small molecule disulfide DTNB has long been used for quantification of free
thiols in proteins (83) as well as to evaluate thiol-disulfide exchange reactions (84), as is
the process catalyzed by TR. As a substrate of TR, DTNB displays Michaelis-Menten
kinetics, but it is not a physiologically relevant substrate, which is reflected by the high
Km values that have been previously reported for this substrate (59, 85, 86). It does,
however, provide a substrate suitable for evaluating the activity of TR mutants that show
little or no activity towards Trx since both the N-terminal and C-terminal disulfide redox
centers are capable of reducing DTNB as has been reported by us (72), and others (85,
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86). A good model for either redox center interacting with DTNB has been previously
presented (73).
For our truncated form of CeTR2 (Table 7, Figure 12), I observe a kcat of 152 ±
14 min-1. This is 113% of the WT enzyme, which has a kcat of 134 ± 7 min-1. The WT and
truncated CeTR2 have comparable Km values. Like the truncated CeTR2, the alanine
insertion mutants also display high activity compared to the WT enzyme. For the single
and double insertion mutants I observe a kcat of 107 ± 4 min-1 and 223 ± 14 min-1, which
result in 70% and 147% of the WT CeTR2 enzyme. This same effect is observed in
DmTR, where alanine insertion between the redox-active Cys residues of the C-terminal
redox center has very little effect on DTNB reductase activity (Error! Reference source
not found.). The Cys-containing DmTR and CeTR2 enzymes have ~12% of the DTNB
reductase activity of the Sec-containing mTR3 (kcat of 157 min-1 for DmTR and 1251 ±
71 min-1 for mTR3, respectively), while their catalytic efficiencies are only 3-fold and 8fold lower than mTR3, respectively.
For the truncated form of mTR3 (Table 9), I observe a kcat of 856 ± 43 min-1. This
is 68% of the semisynthetic WT enzyme, which has a kcat of 1251 ± 71 min-1. The WT
does however, have a significantly lower Km. This is different from what is observed for
the C-terminal mutant of rat TR1 (59) or the truncated form of human TR (87), which
show poor activity. However, this result is similar to a C-terminal mutant of Plasmodium
falciparum TR (PfTR), which had 64% of WT DTNB reductase activity (86). The alanine
insertion mutants (TR-GCAUG and TR-GCAAUG) have slightly elevated activities
compared to the truncated enzyme, but less than the semisynthetic WT enzyme.
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pH Data
The effect of enlarging the C-terminal ring had on the pH rate profile for the
reduction of E.coli Trx was examined. WT CeTR2 data indicates a pH optimum of 7.5,
while for both alanine insertion mutants there was distinct shift in the optimum toward
the alkaline centered between pH 8.0-8.5 (Figure 13).

Conclusions
This investigation examined TRs C-terminal eight-membered ring motif and what
affect enlarging the ring would have on the reduction E.coli Trx. From the data, I
conclude that for CeTR2, the size of the ring is an important factor for the reduction of
E.coli Trx. Another member of the Cys-containing TR, DmTR, similar results was
found. When the ring of the Sec-containing TR, mTR3, was enlarged similarly to the
Cys-containing TRs, activity was not dramatically affected. I conclude that the eightmembered ring structure is essential for the Cys-containing TRs, to have high Trx
reduction activity, while for mTR3 it is not.
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Table 4: CeTR2 thioredoxin reductase activity.
Enzyme
kcat (min-1)
a

610 ± 36

610 ± 60

CeTR2-GCCG-COO-

379 ± 21

247 ± 26

CeTR2-GCACG-COO-

2.6 ± 0.14

111 ± 17

CeTR2-GCAACG-COO-

4.2 ± 0.35

142 ± 31

No Activity

No Activity

b

CeTR2-GCCG-COO- (Intein)

Km (µM)

CeTR2-Truncated

a

I previously reported the activity of CeTR2 produced as an intein-fusion protein in (26).
In the present study, I have used a hexaHis-tag for affinity purification instead of the
intein and I note that the hexaHis-tag enzyme has lower activity.
b
Truncated CeTR2 lacking C-terminal eight amino acids that compose the eightmembered ring motif.
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Table 5: DmTR thioredoxin reductase activity.a
Enzyme
kcat (min-1)
b

Km (µM)

TR-S-COO-

No activity

No activity

TR-SCCS-COO-

299.4 ± 7.4

173.3 ± 8.1

TR-SCACS-COO-

2.12 ± 0.3

298.3 ± 58.0

TR-SCAACS-COO-

0.91 ± 0.2

166 ± 58.0

c

a

Data taken from Ref. (88)
The truncated form of the enzyme missing the C-terminal tripeptide Cys-Cys-Ser.
c
The WT enzyme.
b
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Table 6: Thioredoxin reductase activity of semisynthetic mTR3 enzymes.a
% Peptide
Enzyme
kcat (min-1)
Km (µM)
Incorporation
b,c

mTR3-G-COO-

No activity

No activity

NA

mTR3-GCCG-COO-

4.1 ± 0.11

49.1 ± 3.2

NA

mTR3-GCUG-COO-

2220 ± 78

67.6 ± 6

91

mTR3-GCAUG-COO-

350 ± 14

20.8 ± 3.5

100

mTR3-GCAAUG-COO-

501 ± 41

34.9 ± 10.0

100

b,d

b,e

a

Date taken from Ref. (88)
Reported previously in (72).
c
The truncated form of the enzyme missing the C-terminal tripeptide Cys-Sec-Gly.
d
The full length mutant Sec489Cys.
e
The WT enzyme produced by semisynthesis.
b
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Table 7: DTNB reductase activity for CeTR2.
Enzyme
kcat (min-1)

Km (mM)

kcat / Km
(min-1•mM-1)

a

CeTR2-GCCG-COO- (Intein)

134 ± 5.2

0.42 ± 0.07

319

CeTR2-GCCG-COO-

134 ± 7.1

0.41 ± 0.09

327

CeTR2-GCACG-COO-

107 ± 3.6

0.22 ± 0.04

486

CeTR2-GCAACG-COO-

223 ± 13.8

0.37 ± 0.10

603

CeTR2-Truncated-COO-

152 ± 14

0.53 ± 0.19

287

a

Previously reported in (26).
Truncated CeTR2 lacking C-terminal eight amino acids that compose the eightmembered ring motif.
b
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Table 8: DTNB reductase activity for DmTR.a
Enzyme
kcat (min-1)

Km (mM)

kcat / Km
(min-1•mM-1)

b

DmTR-S-COO-

178.0 ± 7.0

0.75 ± 0.09

237

c

DmTR-SCCS-COO-

157 ± 12.4

0.22 ± 0.07

713

DmTR-SCACS-COO-

187.5 ± 17

0.20 ± 0.06

935

DmTR-SCAACS-COO-

94.9 ± 4.1

0.25 ± 0.03

380

a

Data taken from Ref. (88)
The truncated form of the enzyme missing the C-terminal tripeptide Cys-Cys-Ser.
c
The WT enzyme.
b
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Table 9: DTNB reductase activity for semisynthetic mTR3a
Enzyme
kcat (min-1)
Km (mM)

kcat / Km
(min-1•mM-1)

b

mTR3-G-COO-

856 ± 43

2.72 ± 0.43

314

mTR3-GCCG-COO-

794 ± 78

1.75 ± 0.41

454

mTR3-GCUG-COO-

1251 ± 71

0.46 ± 0.09

2720

mTR3-GCAUG-COO-

1010 ± 26

0.26 ± 0.03

3885

mTR3-GCAAUG-COO-

999 ± 44

0.43 ± 0.08

2323

c

d

a

Data taken from Ref. (88)
The truncated form of the enzyme missing the C-terminal tripeptide Cys-Sec-Gly.
c
The full length mutant Sec489Cys .
d
The WT enzyme produced by semisynthesis.
b
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A

B

C

Figure 10: Structure of the C-terminal Ring motif.
A. Wild-type eight-membered ring. B. Mutant single alanine insertion, creates a elevenmembered ring. C. Mutant double alanine insertion creates a fourteen-membered ring.
In the case on the CeTR2 and DmTR enzymes, X = S of Cys, while in mTR3, X = Se of
Sec.
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Figure 11: Effect of Ring Size on CeTR2 ability to reduce E.coli Thioredoxin.
Thioredoxin reductase activity of CeTR2 WT(●), CeTR2-GCACG (□), and CeTR2GCAACG (◊). Activity is reported in moles of NADPH oxidized per minute per mole of
homodimeric enzyme.
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Figure 12: Effect of Ring Size on CeTR2 ability to reduce DTNB.
DTNB reductase activity of CeTR2 WT(●), CeTR2-GCACG (□), and CeTR2-GCAACG
(◊). Activity is reported in moles of NADPH oxidized per minute per mole of
homodimeric enzyme.
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Figure 13: Effect of Ring Size on CeTR2 ability to reduce E.coli Thioredoxin as a
function of pH.
E.coli thioredoxin reductase activity of CeTR2 WT (●), CeTR2-GCACG (□), and
CeTR2-GCAACG (◊) under varying pH concentrations. Activity is reported as percent
maximal activity of moles of NADPH oxidized per minute per mole of homodimeric
enzyme.
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Chapter 4
Mechanistic Investigation Of C-Terminal Ring Motif
Introduction
To investigate why some TRs utilized Sec and others Cys one must look at the
ring-opening step specifically. To study the ring-opening step on the rate of catalysis, I
have split TR into two parts. The first part is a C-terminal truncation of TR missing the
final eight amino acids (TR∆8). This C-terminal deletion contains the NADPH binding
site, the FAD binding site, as well as the conserved N-terminal dithiol/disulfide. TR∆8
can be produced as a recombinant protein in E. coli as it has been previously
demonstrated that a sixteen amino acid deletion can be made in TR without deleterious
effects on protein stability (87). This is verified by TR∆8 maintaining DTNB reductase
activity even though it lacks the C-terminal redox motif. The remaining eight amino
acids are produced as a synthetic peptide containing the Cys-Cys dyad in the oxidized
form. I have shown that this oxidized peptide is a substrate for the truncated enzyme
(72).

Thus I can do peptide complementation experiments, which involve adding

oxidized C-terminal peptide as the substrate. In this case, the oxidized octapeptide is a
substrate for the enzyme because the ring structure must be reduced during the catalytic
cycle of the enzyme. This will occur whether the peptide is covalently linked to the Cterminus or not. By removing the oxidized octapeptide from the enzyme, I am able to
examine the kinetics of the ring-opening step. The rate at which the disulfides are
reduced will be informative with respect to structure-function relationships.
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As discussed in Chapter 3, the size of the ring is important for CeTR2 and DmTR
catalysis. In addition to exploring the size of the ring in TR catalysis, I want to directly
determine the importance of the ring structure in the ring-opening reaction by
determining the difference in the rate between cyclic and acyclic forms of the oxidized
peptides as shown in Figure 4. The acyclic, oxidized peptide will still have a disulfide
bond, but will have unrestricted rotation, unlike the case in which an intervening peptide
bond connects the two halves of the disulfide, in the cyclic peptide.
This experiment will be repeated with the other two TRs studied in the Hondal
Laboratory, the mouse mitochondrial TR (mTR3) and DmTR. Both of these TRs will
also be truncated so that the last eight amino acids are removed from the C-terminus.
The CeTR2 enzyme and DmTR do not contain Sec, but rather have a vicinal Cys-Cys
dyad at the C-terminus. In studying all three enzymes simultaneously, I can expand the
matrix of experiments to be performed so that not only can the kinetic differences
between the cyclic and linear forms of the oxidized peptides be studied for each enzyme,
but “mutant” peptides can be made in which the penultimate residue can be changed to
Cys or Sec so that the effect of leaving group pKa can be determined for each enzyme.
To also examine the effect of leaving group pKa a peptide containing a mixed disulfide
between Cys and TNB, was designed as a low pKa analog to the Sec peptides, which I
expected to display similar activities. A final peptide in which I refer to as the “switch
mutant” replaces the Cys-Sec dyad with a Sec-Cys dyad. This construct allows for
investigation of which position of the dyad is attacked. This matrix of peptide substrates
is shown in Table 10.
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Materials and Methods
Materials. DTNB, NADPH, were purchased from Sigma-Aldrich (St. Louis,
MO). All other chemicals were purchased from Fisher Scientific (Fair Lawn, NJ) and
were of reagent grade or better. All restriction endonucleases, Vent DNA polymerase,
and T4 DNA ligase were purchased from New England Biolabs (Ipswich, MA) and used
with the supplied buffers according to manufacturer’s guidelines. DNA primers were
purchased from IDT (Coralville, IA).
Cloning of Truncated TRs. Previously the cloning of full-length wild type DmTR
(65) as well as mutant C-terminal variants (88), have been reported. Following identical
cloning conditions from our previous reports, I constructed a truncated DmTR missing
the final eight amino acids (PTPASCCS) from the C-terminus and I term this construct
DmTR∆8. For the cloning of this construct upstream and downstream primers having
respective sequences of 5′- AACAGACATATGGCGCCCGTGCAAGG-3′ and 5′ACAGCCGGTACCTTAGTCCAGTCCGGAGCGCTTGGTGAT -3′ were used to
construct the truncated DmTR for production as a recombinant protein in E. coli cells.
The PCR reaction conditions were described previously in chapter 2, with one notable
addition. For the DmTR∆8 construct, the final concentration of magnesium chloride was
increased to 3mM from 2mM. Without this increase insufficient amplification occurred.
The PCR product and plasmid pTYB1 were each digested with Kpn I and Nde I for 2 h at
37 oC, purified and ligated as previously described. The ligated reaction was background
digested against Eco RI and transformed into E. coli DH5α cells made competent via the
Inoue method (79). DNA from isolated colonies were purified using QIAprep Spin
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Minprep Kit (Qiagen) and screened by restriction analysis using Nde I and Kpn I,
analyzed by analytical 0.8% agarose gel electrophoresis, and positive clones were
verified by sequencing of the DNA coding region.
A truncated CeTR2, missing the C-terminal eight amino acids (PRTQGCCG)
termed CeTR2∆8, was cloned using identical amplification conditions to those described
in chapter 3 and reported previously (88).

The upstream primer of sequence 5′-

ACAGCCCCGGATCCCTTCTCATCAAATAAATTTGATCTG-3′ incorporates a hexahistidine

tag

at

the

N-terminus

and

downstream

primer

of

sequence

5′-

ACAGCCAAGCTTGTCGACTCAGTCTTGTCCAGATCGTTTTGTAAT-3′.
Cloning of truncated mouse TR3,missing the C-terminal eight amino acids
(PTVTGCUG) termed mTR3∆8, was similar to the conditions described above and have
been reported by Flemer (89). For this experiment, plasmid pTR3, which contained the
full-length sequence of the mouse thioredoxin reductase-3 gene (accession #AF171053),
was used as the template DNA. PCR reactions conditions were described in chapter 2,
and the upstream primer was of sequence 5′–AACAGACCATGGGAGGGCAGCAGAG
CTTTG-3′ and the downstream primer was of sequence 5′–ACAGCCGCTCTTCAGC
ATTACTCCAGGCCGGAGCGCTTGGAGAT-3′. The PCR product was then inserted
into plasmid pTYB3 using restriction enzymes Nco I and Sap I to produce a plasmid
capable of producing the recombinant enzyme in E. coli cells. A background digest was
performed with Sal I, BSA, and accompanying Sal I Buffer, for 2 hrs at 37°C, to enhance
the number of positive clones. Following transformation, purified DNA from isolated
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colonies were screened with Nco I and Kpn I. mTR3 contains an internal Kpn I site
which yields two DNA fragments of approximately 500bp and 1000bp yielding the
desired full length insert product of 1500bp.
Purification of Truncated TRs.

For the production of recombinant enzymes

CeTR∆8, DmTR∆8 and mTR3∆8, the constructed plasmids were transformed into E.coli
ER2566 cells and grown overnight on LB plates containing 200 µg/mL ampicillin. A
single isolated colony was inoculated in 100 mL LB media containing 200 µg/mL
ampiciliin and incubated overnight at 37 °C. The overnight inoculum was pelleted by
centrifugation and resuspended in 30 mL of fresh TB media. Three, one-liter pyrex
fernbach flasks, each containing TB media containing a final concentration of 200 µg/mL
ampicillin and supplemented with 20 mg/L of niacinamide, riboflavin and pyridoxine,
were inoculated with 10 mL of resuspended ER25666 E.coli cells. The bacterial growth
was incubated at 37 °C, until the O.D.at 600 nm reached 1.0 at which point the cells were
incubated on ice until the temperature of the culture reached 20 °C. Protein production
was induced by addition of IPTG to a final concentration of 0.5 mM. Cells were grown
overnight at 20 °C and then harvested by centrifugation in a Beckman J21B centrifuge
(7000 xg, 10 min, 4 °C) and stored frozen at –20 °C.
For the purification of the recombinant enzymes DmTR∆8 and mTR3∆8, the
frozen cells were thawed on ice and resuspended in 200 mL of 10 mM potassium
phosphate, 10 mM NaCl, pH 8.0 and incubated with lysozyme (1mg/mL) at 4 °C for 30
min and followed by brief sonication with a Branson 350 Sonifier (Danbury, CT) to
break open any unlysed cells. The cell lysate was cleared by centrifugation in a Beckman
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J21B centrifuge (JA-14 rotor) at 7000 xg for 90 min at 4 °C. The clarified supernatant
was gravity loaded onto DEAE column (2.5 x 16.5 cm, 80 mL) equilibrated with 10 mM
potassium phosphate, 10 mM NaCl, pH 8.0 and washed until the A280 was in the range of
0.10 – 0.05. Protein elution was achieved using a 500 mL linear NaCl gradient of 10
mM-400 mM, in the column buffer. All fractions were analyzed by a Cary 50 UV-vis
spectrophotometer from Varian (Walnut Creek, CA) to determine their absorbance at 280
nm and 460 nm.

Peak fractions were analyzed by 12% reducing SDS-PAGE and

fractions exhibiting A460 and an apparent MW of 55 kDa were pooled and dialyzed into
TE (10 mM Tris, 1mM EDTA, pH 8.0) buffer containing 10 mM NaCl. The dialyzed
protein was incubated on ice in the presence of 20 mM βME for 30 min, followed by
gravity loading onto a column (1.5 x 15 cm, 20 mL) containing 2′,5′-ADP Sepharose 4B
(Amersham Biosciences Pharmacia Biotech, Uppsala,. Sweden) equilibrated with TE
buffer, pH 8.0 with 10 mM NaCl and 20 mM βME. The loaded column was then washed
with buffer until the A280 was below 0.5. The protein was liberated from the column with
TE buffer containing 3.0 M NaCl. Peak fractions were analyzed and pooled based on
their A460 and presence of a 55 kDa band observed on 12% reducing SDS-PAGE. Pooled
fractions were gravity loaded onto a Fast Flow 6 Low Substitution Phenyl Sepharose
(Amersham Biosciences Pharmacia Biotech, Uppsala,. Sweden) column (2.5 x 13 cm, 60
mL) equilibrated with TE buffer, pH 8.0 with 3.0 M NaCl. Following washing with
column buffer, elution was carried out using a 500 mL linear gradient of 3.0 M-0.0 M
NaCl. Fractions were analyzed for A460 content and visualized by 12% reducing SDSPAGE, which indicated protein purity greater than 95%. Pooled fractions were dialyzed
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against 2 x 4L of 50mM potassium phosphate, 300mM NaCl, 1mM EDTA at pH 8.0.
The dialyzed proteins were concentrated via ultracentrifugation and their concentrations
were determined using the ε460 = 22.6 mM-1cm-1.
For the purification of recombinant enzyme CeTR2∆8, ER2566 cells were thawed
and then resuspended in 50 mM potassium phosphate, 500 mM NaCl, 10% glycerol, and
10 mM imidazole at pH 8.0 and incubated with lysozyme (1mg/mL) at 4 °C for 30 min
and then sonicated briefly. The cell lysate was cleared via centrifugation in a Beckman
J21B centrifuge (JA-14 rotor) at 7000 xg for 90 min at 4 °C. The cleared supernatant
was incubated with 20 mM βME for 30 min and then gravity loaded onto Ni-NTA agrose
(Qiagen, Valencia, CA) column (2.5 x 5.0 cm, 20 mL) equilibrated with 50 mM
potassium phosphate, 500 mM NaCl, 10% glycerol, and 10 mM imidazole, pH 8.0 and
then washed with 5 column volumes of buffer. The column was washed a second time
with an additional 5 column volumes with column buffer containing 20 mM imidazole.
Elution of the protein was achieved by addition of buffer containing 250 mM imidazole.
Eluted fractions were dialyzed against 50 mM potassium phosphate, 500 mM NaCl, 10%
glycerol, and 1 mM dithiothreitol (DTT) pH 8.0, to remove imidazole and maintain a
reduced enzyme. Eluent aliquots were concentrated by ultrafiltration using an Amicon
Ultra 30000 MWCO (Millipore) concentrator to 1 mL and loaded onto a PD10 desalting
column composed of Sephadex™ G-25 medium. This purified enzyme remained in
reduced form, and lack the characteristic oxidized 460 peak, making protein
concentration determination difficult. The DTNB assay was used to estimate the amount
of active enzyme present, by comparing its activity to the WT HisCeTR2. Cloning and

67

production of full-length wild-type mTR3(72), DmTR(65), and CeTR2 (88) have
described previously. In this report the full-length enzymes are respectively abbreviated
as mTR3-GCUG, DmTR-SCCS, and CeTR2-GCCG to indicate the sequence of their Cterminal redox active tetrapeptides.
Synthesis of Peptide Substrates. The amino acid sequence of cyclic and acyclic
octamer peptides was chosen based upon the sequence of the C-terminus of each
respective TR used in this study; PTVTGCUG for mTR3, PTPASCCS for DmTR, and
PRTQGCCG for CeTR2. The procedure for the synthesis of the cyclic and acyclic
versions of the C-terminal peptide for mTR3 has been recently published (89) and the
corresponding peptides for DmTR and CeTR2 were synthesized using the same
procedure. A peptide containing a mixed disulfide between Cys1 of the peptide and 5thio-2-nitrobenzoate that I termed Pep-TNB (shown in Figure 4), was synthesized for
this study. A third type of peptide was synthesized that was of sequence AA1-AA2-AA3AA4-Sec1-Cys2-AA7-AA8 that I term the “switch peptide” because the position of the Cys
and Sec residues have been exchanged. A switch peptide was made for mTR3 and
DmTR using the native sequence of the respective enzyme for the remaining residues in
the octapeptide. The procedure for the synthesis of the switch peptide was identical to
that for cyclic peptides described by Flemer (89).
DTNB Reductase Activity. The TR∆8 constructs were assayed for activity toward
DTNB, as described by Arner (70). All assays were performed on a Cary 50 UV-vis
spectrophotometer from Varian (Walnut Creek, CA) at 25 °C and pH 7.0 and were
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initiated by addition of enzyme. The concentration of homodimeric TR was determined
using the flavin extinction coefficient of 22.6 mM-1•cm-1 (70). Activity was monitored
over 2 min with Vo determined from the linear fit. Plots of Vo/ET versus substrate
concentration were fit by the Michaelis-Menten equation using KaleidaGraph 4.02 from
Synergy Software (Reading, PA), and activities are reported as moles of NADPH
consumed per minute per mole of TR dimer.
The DTNB assay contained 0.2 mM NADPH and 10 mM EDTA in 100 mM
potassium phosphate. For each concentration of DTNB, activity was corrected for
background by addition of buffer only. Activity was measured by the increase in
absorbance at 412 nm, calculated using the extinction coefficient for TNB-S- (5-thio-2nitrobenzoate, 13.6 mM-1•cm-1), and divided by 2 to account for the production of two
TNB-S- molecules per NADPH consumed. The concentrations of enzyme used in the
assay were 2 nM of mTR3∆8, 5 nM of DmTR∆8, and 5 nM of CeTR2∆8.
Assays using Peptide Disulfides as Substrates. All lyophilized peptides were
weighed and resuspended in a minimal amount of 500 mM potassium phosphate, pH 7.0,
to create a working stock solution of peptide in the range of 30 – 60 mM. The peptide
complementation assay contained 0-25 mM peptide, 150 µM NADPH, 1 mM EDTA, in
50 mM potassium phosphate at pH 7.0 in a volume of 500 µL. Background activity was
corrected for each concentration of peptide by performing an assay in which buffer was
added instead of the peptide solution. A second control was performed in the presence of
enzyme with peptide missing from the assay. Activity was measured by the decrease in

69

absorbance at 340 nm for the consumption of NADPH and calculated using an extinction
coefficient of 6200 M-1•cm-1. The concentrations of TR∆8 and corresponding peptides
used in the assay are presented in Table 11. The concentration of each truncated TR was
adjusted to achieve a signal to noise ratio that allowed a range of peptide concentrations
to be assayed.
When Pep-TNB was used as a substrate the assay conditions were identical to
those discussed above except that a wavelength of 412 nm was used to follow the release
of the TNB anion over time.
pH Optima of DTNB Reduction. Activity toward DTNB was tested as a function
of pH for constructs mTR3-GCUG, mTR3∆8, DmTR-SCCS, and DmTR∆8. Each assay
contained buffer with a final concentration of 100 mM sodium acetate, MES, Tris, and
dibasic potassium phosphate adjusted from pH 5.0 to 10.0 in intervals of 0.5 pH units.
Each assay contained 150 µM NADPH and 1 mM EDTA. The concentrations of enzyme
and DTNB for each of the assays were as follows: 4 nM mTR3-GCUG/2.5 mM DTNB, 3
nM mTR3∆8/2.5mM DTNB, 4 nM DmTR-SCCS/1.0 mM DTNB, 5nM DmTR∆8/5.0
mM DTNB. The activity was measured at 412 nm and background corrected. The data
were collected in triplicate, then normalized to the percent of maximal activity for each
given construct, and plotted as percent maximal activity versus pH.
pH Optima of Peptide Reduction. The truncated TR enzymes were tested for their
ability to reduce their cognate C-terminal peptides as a function of pH. The final 500 µL
reaction contained 100 mM each of MES, sodium acetate, potassium phosphate (dibasic),
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and Tris, 1 mM EDTA, 0.150 mM NADPH. Concentrations of the enzymes and peptides
assayed were as follows: 10 nM mTR3∆8/2mM cyclic PTVTGCUG, 50nM mTR3∆8/2
mM acyclic PTVTCGUG, 15nM mTR3∆8/0.5mM acyclic PTVTGC-TNB, 50nM
DmTR∆8/1mM acyclic PTPASCUS, and 25nM DmTR∆8/0.5 mM acyclic PTPASCTNB. Activity was monitored for changes in A340/min or A412/min as described above.
Each pH point was assayed in duplicate or triplicate and were background corrected
against the spontaneous reduction of NADPH at acidic pH.

Results
Purification of Enzymes. mTR∆8 and DmTR∆8 proteins were purified using
three different chromatographic steps to homogeneity as judge by SDS-PAGE as shown
in Figure 14. Protein yields for mTR∆8 and DmTR∆8 were 32 mg/L and 156 mg/L of
culture, respectively. The clone for CeTR2∆8 contained a hexa-histidine tag, which
allowed for a single step purification by an affinity column and had a similar purity as the
other TRs in this study as judged by SDS-PAGE (Figure 14). The protein yield for
CeTR2∆8 was 35 mg/L of cell culture.
DTNB Reductase Activity. In this study I created truncated TRs missing their
final eight amino acids and evaluated their ability to reduce DTNB. A summary of the
kinetic data is presented in Table 12. All truncated enzymes maintained their ability to
reduce DTNB at comparable rates compared to their corresponding WT enzymes.

In

the case of mTR3∆8, its kcat increased 2.3-fold, while Km also increased 1.8-fold,
resulting in nearly identical catalytic efficiency compared to its WT enzyme. DmTR∆8
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followed a similar pattern, its kcat increased 8.2-fold, while its Km increased 18.6-fold,
resulting in a decrease in catalytic efficiency of 2.3-fold. The kinetic constants for
CeTR∆8 were essentially the same as its full-length enzyme.
Assays using Peptide Substrates.
transferred

from

the

N-terminal

During the catalytic cycle electrons are

disulfide

redox

center

to

the

C-terminal

disulfide/selenylsulfide redox center. Truncated TRs are capable of reducing peptide
disulfides/selenylsulfides that correspond to their missing C-terminal sequence (ring
opening step – Figure 15) (65, 72) (89). Using this property of TR, I was able to
evaluate the relative importance that the unique eight-membered ring makes to the
catalytic rate. This is accomplished by comparing the turnover rate of cyclic and acyclic
peptide disulfide/selenylsulfide substrates. In each instance the WT amino acid sequence
was oxidized creating a disulfide/selenylsulfide linkage, resulting in the formation of a
cyclic intrachain or an acyclic interchain peptide.

The cyclic intrachain

disulfide/selenylsulfide results in the formation of a strained eight-membered ring, while
the interchain disulfide/selenylsulfide linkage results in an acyclic peptide lacking this
strained eight-membered ring. One important feature of this study is to compare the
importance of the ring structure between Sec-containing and Cys-containing TRs. Thus
for a Sec-containing TR the relevant comparative rates are for the cyclic Se-peptide and
the acyclic Se-peptide (X = Se in Figure 4), and for a Cys-containing TR the relevant
rates are the cyclic S-peptide and the acyclic S-peptide (X = S in Figure 4).

The second

order rate constants for these peptide turnover rates are given in Table 13 (Kinetic plots
for which these rates are derived are provided in Figure 16, Figure 17, and Figure
72

18) and the important ratios for comparison are summarized in Table 14. The data in
Table 14 indicate that the eight-membered ring contributes moderately to the catalytic
rate for the Sec-containing mouse enzyme since the ratio of cyclic to acyclic peptides is
32, however the data indicates that the eight-membered ring is of much greater
importance for the Cys-containing TRs from D. melanogaster and C. elegans as the ratio
of turnover rates for cyclic and acyclic peptides is 1025 and 2267, respectively.
“Mutant” peptides were also constructed in which the penultimate residue was
changed from Sec to Cys (mTR3) or Cys to Sec (DmTR, CeTR2) for both the cyclic and
acyclic peptides. These peptides were assayed as substrates for their respective enzymes.
The results given in Table 13 indicate that S for Se substitution has dramatic effects on
the catalytic rate for both the cyclic and acyclic peptides in the case of the mammalian
enzyme (8667-fold lower and 410-fold lower, respectively).

Conversely, Se for S

substitution improves the turnover rate by 12-fold in the case of DmTR (compare 41 to
499) or only moderately decreases the rate by 2.8-fold in the case of CeTR2.
Interestingly, the acyclic Se-peptide has comparable activities to the cyclic S-peptide in
the cases of DmTR and CeTR2. While the acyclic Se-peptide has moderately lower
activity than the cyclic Se-peptide in the case of the mammalian enzyme, the acyclic Sepeptide has much higher activity than the cyclic S-peptide (167-fold) with mTR3. This
indicates that the presence of a selenium atom in the peptide contributes much more to
the rate than does the presence of the ring in the case of the mammalian enzyme. In the
case of the Cys-containing TRs, the selenium atom in the penultimate position makes a
near equal contribution to the rate in comparison to the ring since the activity of the
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acyclic Se-peptide has a similar rate to the cyclic S-peptide.

These two facts are

supportive of a strong leaving group effect in the ring opening reaction. This hypothesis
is supported by the data using Pep-TNB as a substrate for all three enzymes. This
substrate contains a highly reactive mixed disulfide bond due to the presence of the 5thio-2-nitrobenzoate group. The sulfur atom of this moiety has a pKa of 4.75 (90),
comparable to that of a selenol (5.2, (91)). The assay results using this substrate indicate
that it has similar activity to the cyclic, WT peptide for each respective enzyme. For
example, the turnover rate for Pep-TNB is 220 min-1•mM-1 for mTR3 while the cyclic
Se-peptide has a turnover rate of 260 min-1•mM-1 (Table 13). Similar results are shown
for the Cys-containing TRs in Table 13.

Further strength of this leaving group

hypothesis is given by the ratio of acyclic Se-peptide/acyclic S-peptide turnover rate for
all three enzymes listed in Table 14. This ratio is of similar magnitude in all three cases
indicating the importance of the lower pKa selenol in comparison to that of the thiol (5.2
vs. 8.3).
Additionally a “switch” mutant was constructed in which a cyclic selenylsulfide
linkage was made, however the positions of Sec and Cys were “switched” so that Sec was
in the first position of the dyad. The mammalian enzyme had an activity of 0.23 min1

•mM-1 using this peptide substrate, which is 1130-fold lower than the cyclic peptide in

which Sec is in the second position of the dyad (260 min-1•mM-1). In comparison DmTR
had an activity of 4.6 min-1•mM-1 using this switch peptide, which is a 109-fold drop in
comparison to the peptide with Sec in the second position of the dyad (499 min-1•mM-1).
The lower effect of the switch mutant on the Cys-containing TR is likely due to the fact
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that a sulfur atom must be in the leaving group position when this ring is open since it
contains a Cys1-Cys2 dyad. Thus the drop in activity for DmTR using the switch peptide
as substrate must be due to the fact that the sulfur atom of CysIC must attack a more
electronegative atom. The effect of this mutation is illustrated in Error! Reference source
not found.. This result strongly argues for the second residue of the dyad (either Cys2 or
Sec2) to be in the leaving group position during the ring opening step.
pH Optima of DTNB Reduction. To evaluate the pH dependence of the reduction
of DTNB in the truncated enzymes and their full-length WT counterparts, I performed pH
rate profiles (Activities are indicated in Table 15). The truncated mouse enzyme shows a
pH optimum for the reduction of DTNB at pH 6.5, while truncated DmTR has a pH
optimum at one pH unit higher as shown in Figure 20A. For comparison the pH rate
profiles for the full-length enzymes are shown in Figure 20B. For the full-length mouse
enzyme the pH optimum is shifted to 7.0-7.5.

The full-length enzyme from D.

melanogaster also showed a basic pH shift to pH 8.5. The results indicate that the Cterminal redox center causes a shift in the pH optimum for both enzymes.
pH Optima of Peptide Reduction.

The pH dependence for the reduction of

peptides containing Sec or a mixed disulfide with TNB were assayed with their
corresponding truncated TR (Figure 21, Table 16). Figure 21A shows pH rate profiles
comparing activity of mTR3∆8 with acyclic PTVTGCUG and DmTR∆8 with acyclic
PTPASCUS and their pH optima’s were determined to be 7.9 and 8.4, respectively. The
cyclic PTVTGCUG peptide had comparable pH optima of 8.4 with mTR3∆8 (data not

75

shown). The pH dependence of the reduction of the acyclic peptides PTVTGC-TNB and
PTPASC-TNB with their cognate truncated enzymes is shown in Figure 21B. The
mTR3∆8 enzyme has a pH optima of 6.0, while the DmTR∆8 pH optima shifts ca. 1.52.0 units, to between 7.4-7.9. It was observed at pH 6.0 and to a lesser extent pH 6.5, the
A412/min with PTVTGC-TNB deviated from linearity, showing a initial burst and then
lagging. I believe that the enzymes CysIC is forming a stable mixed disulfide with
PTVTGC and the initial burst can be contributed to the initial reaction of peptide and
with TR resulting release of TNB-S-. This however was not a stiochiometric event
indicating there was turnover following initial burst phase, just severely impaired.

Conclusions
The data presented here in this chapter reveals details into the mechanistic
differences between the two classes of TR.

The truncated TRs were purified and

exhibited high DTNB reductase activities. The ability for the truncated enzymes to
turnover DTNB is excellent evidence for having correctly folded and functional enzyme.
This allowed for more elaborate experiments using cyclic and acyclic peptides that mimic
the removed C-terminal sequence, to investigate the mechanism of “ring opening”
between the vicinal Cys1-Cys2 or Cys1-Sec2 dyads.
These experiments allow one to conclude that, firstly, based on the activities of
the ratios of the WT cyclic peptides vs. the WT acyclic peptides, the eight-membered ring
structure is much more important for the Cys-containing class of TRs (CeTR2, DmTR)
than to the Sec-containing member, mTR3. Second, for mTR3, the Se atom is much
more important than the ring structure. This comes from the fact that the acyclic Sec
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peptide had 273-fold more activity than the cyclic Cys peptide. For the Cys-containing
TRs, the cyclic Cys peptide had higher rates than the acyclic Sec peptides though were of
similar magnitudes (1.3 and 7.2-fold decreases in activity). These results suggest that the
Cys1-Cys2 ring is important for enhancing Cys2 ability to act as a better leaving group
during ring opening, while Sec does not need the ring structure because it low pKa makes
it a good leaving group. This is supported by the rates determined for the acyclic
Peptide-TNB construct. The TNB group, utilizes a S atom, however is a much better
leaving group than Cys, due to its lower pKa. This peptide behaves similarly to the
acyclic Sec peptides, and restores activity to near the WT cyclic peptides rates. Lastly,
the poor activity of “switch” mutant peptides, reveal that position 1 of the dyad must be
attacked by the CysIC residue during ring opening.
To examine the mechanism further, pH profiles comparing the activities of the
truncated mTR3 and DmTR enzymes with DTNB, acyclic Sec peptides and their PepTNB construct. The results indicate that there are differences between the two enzymes
ability to reduce these substrates. The mTR3∆8 is capable of reducing these substrates at
lower pH compared to DmTR which has implications for mechanistic differences which
will be discussed in chapter 5.
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Table 10: Summary of Peptide Complementation Experiments to be Performed
Between Truncated Enzyme and Cognate, Oxidized Peptide.a
Peptide
Enzyme
Sequence
CeTR2∆8

DmTR∆8

CG

PTPASC

WT acyclic
peptide

PRTQGC

WT cyclic
peptide

PRTQGCCG

PTPASCCS

PTVTGCUG

Mutant acyclic
peptide

PRTQGC

PTPASC

PTVTGC

Mutant cyclic
peptide

PRTQGCUG

PTPASCUS

PTVTGCCG

Acyclic TNB
peptide

PRTQGC TNB

PTPASC TNB

PTVTGC TNB

Cyclic “switch”
peptide

Not Synthesized

PTPASUCS

PTVTGUCG

UG

a

CS

mTR3∆8

US

PTVTGC

UG

CG

For each truncated TR shown above, each will be assayed with its cognate, oxidized
peptide in the cyclic and acyclic form. In addition, each truncated enzyme can be
assayed with the cyclic and acyclic forms of the peptide in which the penultimate amino
acid is replaced with Sec or Cys (depending on the original WT sequence).
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Table 11: Truncated TR and Peptide Concentrations used in Peptide
Complementation Experiments.
Peptide
Cyclic PTVTGCUG
Acyclic PTVTGCUG
Cyclic PTVTGCCG
Acyclic PTVTGCCG
Cyclic PTVTGUCG
Acyclic PTVTGC-TNB
Cyclic PTPASCCS
Acyclic PTPASCCS
Cyclic PTPASCUS
Acyclic PTPASCUS
Cyclic PTPASUCS
Acyclic PTPASC-TNB
Cyclic PRTQGCCG
Acyclic PRTQGCCG
Cyclic PRTQGCUG
Acyclic PRTQGCUG
Cyclic PRTQGC-TNB

Concentration Range
0-20.0mM
0-7.5mM
0-20.0mM
0-20.0mM
0-7.5mM
0-2.0mM
0-25.0mM
0-20.0mM
0-1.0mM
0-10.0mM
0-10.0mM
0-5.0mM
0-11.0mM
0-10.0mM
0-10.0mM
0-10.0mM
0-10.0mM
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Enzyme

Concentration

mTR3-∆8
mTR3-∆8
mTR3-∆8
mTR3-∆8
mTR3-∆8
mTR3-∆8
DmTR-∆8
DmTR-∆8
DmTR-∆8
DmTR-∆8
DmTR-∆8
DmTR-∆8
CeTR2-∆8
CeTR2-∆8
CeTR2-∆8
CeTR2-∆8
CeTR2-∆8

3nM
50nM
2000nM
2000nM
1000nM
15nM
25nM
2000nM
5nM
50nM
500nM
50nM
20nM
2000nM
60nM
60nM
20nM

Table 12: Kinetic Constants for the Reduction of DTNB
Enzyme
kcat (min-1)
Km (mM-1)
mTR3-GCUGa
1251 ± 71
0.45 ± 0.09
mTR3-∆8
2905 ± 232
0.83 ± 0.27
a
DmTR-SCCS
157 ± 12
0.22 ± 0.07
DmTR-∆8
1294 ± 277
4.1 ± 2.1
CeTR2-GCCGb
134 ± 7
0.41 ± 0.09
CeTR2-∆8
152 ± 14
0.53 ± 0.19
a
Reported in ref. (88).
b
Reported in supplemental of ref. (88).
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kcat/Km (min-1•mM-1)
2720
3500
713
316
327
287

Table 13: Rate Data for Truncated TRs using Peptide Disulfides as Substrates.
Substrate
Enzyme (octapeptide)
Rate (min-1•mM-1)
mTR3∆8
DmTR∆8
CeTR2∆8
(PTVTGCUG) (PTPASCCS) (PRTQGCCG)
Cyclic Se-peptide
260 ± 44a
499 ± 24
49 ± 4
a
Acyclic Se-peptide
8.2 ± 1.4
31 ± 0.4
19 ± 3.3
Cyclic S-peptide
0.03 ± 0.003a
41 ± 1.5
136 ± 34
Acyclic S-peptide
0.02 ± 0.001a
0.04 ± 0.001
0.06 ± 0.03
Cyclic “Switch” peptide
0.23 ± 0.012
4.6 ± 0.04
NDb
a
DTNB
3500 ± 578
316 ± 79
287 ± 37
Peptide-TNB
220 ± 62
21 ± 0.45
32 ± 9
a

From Ref. (89)

b

ND = Not determined
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Table 14: Ratio of Turnover Rates of Peptide Substrates.
Enzyme
Cyclic Se/
Acyclic-Se/
Cyclic WT/
Cyclic-S
Acyclic-S
Acyclic WT
mTR3∆8
DmTR∆8
CeTR2∆8

8667
12
0.4

410
775
317
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32
1025
2267

Table 15: pH Dependence of Reduction of DTNB
pH
mTR3-GCUG
mTR3∆8
DmTR-SCCS
5.0
8.88a
8.58
ND
5.5
32.48
70.26
10.72
6.0
422.49
935.87
48.41
6.5
945.16
1570.67
189.34
7.0
1056.68
1409.72
216.30
7.5
1062.19
1149.10
226.41
8.0
849.88
810.05
233.46
8.5
733.15
383.17
246.63
9.0
617.03
330.47
205.58
9.5
481.62
NDb
168.50
10.0
368.57
ND
98.65
a
Activities reported as moles of NADPH oxidized/min/mole TR.
b
ND = Not Determined
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DmTR∆8
ND
ND
259.80
612.01
797.06
974.02
900.25
800.00
570.83
313.73
123.04

Table 16: pH Dependence of Reduction of Peptides Substrates
pH
Cyclic
Acyclic
Acyclic
Acyclic
PTVTGCUGa PTVTGCUGa PTVTGC-TNBa
PTPASCUSb
5.5
69.13c
17.04
1.72
0.64
6.0
83.60
21.22
59.80
4.18
6.5
114.15
32.48
134.64
11.25
7.0
173.63
41.80
138.89
18.65
7.4
223.47
63.99
125.16
29.58
7.9
239.55
67.20
113.40
29.26
8.4
252.41
65.59
89.05
35.05
8.9
205.79
61.74
59.80
24.44
9.4
176.85
58.52
37.91
22.19
9.8
146.30
51.77
23.53
16.40
a
Assayed with mTR3∆8.
b
Assayed with DmTR∆8.
c
Activitiy is reported as moles of NADPH oxidized/min/mole TR.
d
ND = Not Determined.
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Acyclic
PTPASC-TNBb
NDd
10.29
20.01
24.51
26.86
26.72
20.81
12.99
7.84
5.39

Figure 14: SDS-PAGE of Purified TRs
A 12% reducing SDS-PAGE showing purity of enzymes used in this study. Lane 1,
TriChromRanger™ prestained protein molecular weight marker mix, Lot:IE0014 (Pierce,
Rockford, IL), lane 2, HisCeTR2, lane 3, HisCeTR2∆8, lane 4, DmTR, lane 5, DmTR∆8,
lane 6, semi-synthetic mTR3, lane 7, mTR3∆8.

85

A

B

C

D

86

Figure 15: TR has a conserved enzymatic mechanism.
A.) Full length TR accepts reducing equivalents from NADPH, which transfers a hydride
to a non-covalently bound FAD cofactor. The N-terminal redox active center is reduced
to form a charge transfer complex (FADH--SHCT), while the interchange Cys (SHIC)
attacks the C-terminal redox center of the neighboring subunit (designated with prime (‘)
and shown in red), which I refer to as the “ring opening step”. Following this “ring
opening step”, the nucleophile (Nuc’X) forms a mixed disulfide with Trx and is resolved
by the vicinal Cys (Res’SH) to reform the eight member ring. B.) To determine the
contribution the “ring opening step” has to the rate of Trx reduction, I constructed a
truncated TR lacking the C-terminal eight residues. Cyclic and acyclic peptides (red)
(see Figure 4) corresponding to the C-terminal sequence can be reduced by the truncated
enzyme, and a rate determined (see Table 13). C.) GR is in essence a truncated TR
missing its C-terminal sixteen residues and GSSG (red) is analogous to the TR Cterminal redox center. D.) Truncated TR is incapable of reducing linear disulfide
substrates such as GSSG or cystine, whiles the highly reactive disulfide DTNB (red), and
is readily reducible.
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Figure 16: Peptide Complementation Kinetic Plots of CeTR∆8.
A. Cyclic PRTQGCCG B. Acyclic PRTQGCCG. C. Cyclic PRTQGCUG. D. Acyclic
PRTQGCUG. E. Acyclic PRTQGC-TNB.
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Figure 17: Peptide Complementation Kinetic Plots of DmTR∆8
A. Cyclic PTPASCCS. B. Acyclic PTPASCCS. C. Cyclic PTPASCUS. D. Acyclic
PTPASCUS. E. Acyclic PTPASC-TNB. F. Cyclic PTPASUCS.
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Figure 18: Peptide Complementation Kinetic Plots of mTR3∆8.
A. Cyclic PTVTGCUG. B. Acyclic PTVTGCUG. C. Cyclic PTVTGCCG. D. Acyclic
PTVTGCCG. E. Acyclic PTVTGC-TNB. F. Cyclic PTVTGUCG.
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A

B

Figure 19: Effect of selenium on “ring opening”
A.) In the wild type case, the eight-membered ring is composed of the Cys1-Sec2 dyad.
The interchange thiolate attacks the electrophilic S of Cys1 allowing the Se of Sec2 to act
as the leaving group. B.) The “switch” mutant peptide eight-membered ring is composed
of the Sec1-Cys2 dyad. In this instance, the interchange thiolate attacks the more
electronegative Se atom of Sec1, which is less reactive and forces the poorer leaving
group S of Cys2 to leave.
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A

B

Figure 20: Activity toward DTNB as a function of pH for Thioredoxin Reductase.
A.) Truncated mTR3∆8 (■) and truncated DmTR∆8 (○). B.) Full length mouse wild type
enzyme mTR3-GCUG (■), full length wild type DmTR-SCCS (○). Results are reported
as a percentage of the maximal activity for each plot.
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B

Figure 21: Activity of truncated TR toward peptide substrates as a function of pH.
A.) Truncated mTR3∆8 assayed with acyclic PTVTGCUG (■) and truncated DmTR∆8
assayed with acyclic PTPASCUS (○). B.) Truncated mTR3∆8 assayed with acyclic
PTVTGC-TNB (■) and truncated DmTR∆8 assayed with acyclic PTPASC-TNB (○).
Results are reported as a percentage of the maximal activity for each plot.
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Chapter 5
Proposed Mechanism
Discussion
A key question in seleno-enzymology is why certain enzymes have evolved the
rare and unique Sec residue which requires intricate recoding machinery for interpreting
the UGA opal stop codon as a sense codon for Sec (92, 93). In the case of TR, it had
always been assumed that the selenium atom was required for efficient nucleophilic
attack on the disulfide bond of Trx, but this notion was largely dispelled by Kanzok and
coworkers who showed that DmTR has very high activity towards its cognate Trx as well
as the E. coli substrate (25). Further support for the unimportance of Se in the reaction
was given in chapter 2, showing that the CeTR2 is also capable of utilizing Cys to reduce
E.coli Trx, even with out the aid of flanking Serine residues (26). The work presented
here builds on our previous work, which put forth the hypothesis that the Sec residue is
required in the ring opening step of the reaction for the mammalian enzyme. I summarize
the evidence for this hypothesis below.
Previously, Eckenroth has demonstrated that a truncated TR∆3 could be used to
reduce oxidized tetrapeptides, corresponding to the wild type and mutant C-terminal
sequence of mTR3 (GCUG, GCCG) and DmTR (SCCS, SCUS), respectively.
Evaluation of the ratio of rates of the ring opening step for Se/S containing peptides
indicated that the Se atom was more important to mTR3 (308-fold rate reduction) enzyme
than it was for DmTR (5.65-fold rate reduction) enzyme (65).
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When the C-terminal vicinal Cys1Cys2 and Cys1Sec2 residues are oxidized, a
strained eight-membered ring is formed. NMR structural determinations of tetrapeptides
indicate that Cys1Cys2 peptides undergo cis/trans equilibrium, while the Cys1Sec2 peptide
is predominately forced into a trans conformation (Deker, unpublished work).

To

investigate the importance of the ring to catalysis, substrate docking studies predicted that
the Cys1Cys2 containing enzymes ability to switch conformations of the ring is necessary,
indicating that upon reduction of the cis conformation, Cys2 is in position for proton
extraction from a conserved histidine, stabilizing the Cys2 thiolate enhancing its ability to
act as a good leaving group. Conversely, proton extraction is not possible when Sec2 is in
the trans conformation, however it is not necessary since the selenolate anion is a better
leaving group than the thiolate because of its lower pKa.
These observations led us to investigate the importance of the eight-membered
ring in the catalytic cycle. As stated in chapter 3, this hypothesis was evaluated by
constructing mutant enzymes possessing one or two alanine residues inserted between the
vicinal Cys1Cys2/Sec2 dyads of mTR3, DmTR, and CeTR2. These insertions had the
effect of expanding the ring size (eleven and fourteen vs. eight-membered rings) and
relieving ring strain. By expanding the ring size, Cys2/Sec2 becomes separated away
from the conserved histidine, resulting in loss of activity. The effect of these single and
double alanine insertions on the reduction of E.coli Trx indeed showed a decrease in rate
compared to the WT rate of 4-6-fold, 150-300-fold, and 90-145-fold for mTR3, DmTR,
and CeTR2, respectively. The fact that mTR3 insertions resulted in only a modest
decrease in activity while both DmTR and CeTR2 had more dramatic losses in activity is
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strong evidence in favor of our hypothesis that the ring structure is more important for the
Cys containing TRs, than the Sec containing mTR3.
In this study I also considered why some TRs utilize Sec, while others exploit
Cys, during their catalytic cycle. To investigate this, peptide complementation was used.
This technique takes advantage of the ability of truncated TRs to reduce cyclic and
acyclic octapeptides, corresponding to their missing C-terminal sequences.

A

comparison of the catalytic efficiencies of peptides containing either sulfur or selenium,
in the penultimate position, provides insights into their roles in the ring opening process.
The ratios of rates of the ring opening step for cyclic Se/cyclic S containing peptides
verified that the Se atom was more important to mTR3 (8667-fold) enzyme than it was
for DmTR (12-fold) and CeTR2 (0.36-fold) enzymes. Additionally, comparisons of the
ratios for the rates of the WT cyclic/acyclic peptides reveal that, for mTR3 (32-fold loss
in activity), the ring structure is not as important for activity, while in the case of the Cyscontaining enzymes DmTR (1025-fold loss in activity) and CeTR2 (2267-fold loss in
activity), a large decrease in activity demonstrates that the eight-membered ring is
important for catalysis. I believe that this result supports that the eight-membered ring
must be pertinent for aligning Cys2 with the conserved histidine to allow for protonation
of the leaving group, thus for the Cys class of TRs, it is the ring that allows for optimal
activity when utilizing a S atom. For mTR3, the Se atom is necessary for activity, and its
presence is more important that the ring structure. This is demonstrated by the acyclic Se
peptide having 273-fold more activity than with the cyclic S peptide (compare 8.2 min1

•mM-1 with 0.03 min-1•mM-1). All three truncated enzymes were also assayed with
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acyclic peptides containing Cys and Sec in the penultimate position. By comparing the
ratios of the rates for these peptides, the effect of leaving group chemistry on the reaction
can be evaluated. Sec is a better leaving group than Cys because of its low pKa. This is
observed by acyclic Sec peptides being more reactive than the acyclic Cys peptides. A
comparison of theses results reveal similar differences in rate loss among the three
enzymes: mTR3∆8 (410-fold loss), DmTR∆8 (775-fold loss) and CeTR2∆8 (317-fold
loss). This result supports that the leaving group effect is the predominate driving force
resulting in activity. Thus for mTR3, the incorporation of a Se atom is essential for
maintaining a good leaving group, where as for the Cys-containing TRs, the eightmembered ring and its proximity to the critical acid catalyst histidine, allows the S atom
to act a good leaving group in a similar matter to Se. This is illustrated in Figure 22.
To verify this observation the truncated enzymes were assayed for activity with an
acyclic C-terminal peptide analog conjugated with a mixed disulfide with the highly
reactive, low pKa, TNB compound.

This resulted in rescuing activity of the Cys-

containing peptides to comparable levels with the Sec-containing peptides. The ratios of
Pep-TNB/acyclic S-peptides show fold-rate enhancements of 11000, 525 and 533 for
mTR3, DmTR and CeTR2, respectively. The substitution of a better leaving group like
TNB in place of Cys, resulted in restoring the lost activity to a comparable rate similar to
the acyclic Se peptides. These results add to the support that the leaving group is
important.
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The poor activities of the cyclic “switch” mutants (Sec1-Cys2 dyad), indicate that
the AA1 (of the dyad) position must be involved in the attack from the interchange CysIC
during the ring opening step.
The results of enlarging the ring and the ratio of the peptide complementation
rates of the WT cyclic/acyclic peptides indicate that the ring structure is of only moderate
importance for the Sec containing mTR3, while it is essential for the Cys contain DmTR
and CeTR2. The results of the investigation into the role of Sec or Cys in the ring
opening step indicate that their role is involved as the leaving group. For the Cys
containing TRs, the leaving group is very important. The ring structure makes Cys a
better leaving group by positioning it for protonation by a conserved histidine that acts a
general acid. When the ring is disrupted, as in the acyclic S-peptide, the leaving group is
disengaged from the general acid, which prevents protonation, and results in extremely
poor activity. The activity can be restored by substituting Cys with a good leaving group
like Sec or TNB. For the Sec-containing TR, the Sec leaving group is very important,
indicated by the severe loss in activity when a Cys residue was substituted in its place and
restored by the TNB moiety. Also the “switch” mutant results indicate the Sec must be in
the second position of the dyad to be active. The data indicates that the Sec containing
ring disconnects the leaving group from the general acid, however, because of Sec low
pKa results in the selenolate, which can over come the disconnection.
The data suggests that for the Cys TRs, are two questions are related. The ring is
important for positioning the leaving group Cys near the His, which makes Cys a good
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leaving group and for the Sec TR the ring is of less importance because it contains a low
pKa leaving group and does not require protonation.
This investigation indicates that the differences in the two classes of TRs
mechanism occur in the ring opening step. Why does the Sec TR need a low pKa leaving
group? The pH rate profile data with the truncated enzymes indicated distinct pH optima
between mTR3 and DmTR. Of these enzymes, the full length and truncated forms of
each were characterized for their pH dependence for the reduction of the small molecule
DTNB. Addition of the C-terminal redox active site, in the full length enzymes, caused a
shift in the optimal pH toward the alkaline. It has been shown that the pKa’s for the
CysCT (4.8), CysIC (6.2-7.5) and His (9.2) acid/base catalyst of yeast GR could shift
dramatically, from the usually expected values (94-96). Since the truncated TRs used in
this study resemble GR, it is suitable to use the pKa values of yeast GR since there is high
degree of homology among the active site titratable groups.

In this reaction the CysIC

thiolate needs to be stabilized by the proton on His before it can attack the S atom of
DTNB. The stabilization of the thiolate would be rate limiting step. The CysCT residue
would be ionized and capable of resolving the formed mixed disulfide between CysIC and
TNB completing the enzymatic cycle. In the case of the full length WT TRs, DTNB is
reduced either by the N-terminal or C-terminal redox center. The histidine residue would
still be critical for stabilizing the CysIC thiolate for attack either on the C-terminus or
DTNB substrate.
To look at the effect Sec has on the protonation events occurring in the active site,
I performed a similar experiment as with DTNB, but replaced the substrate with acyclic
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Sec containing peptides. I expected similar results as obtained through the DTNB data.
However, instead I observed a pH shift toward the alkaline. A possible explanation for
this is that the pKa of Sec is not as close to the pKa of the TNB-S- (5.2 vs 4.75) as
indicated in the literature. It is known that the pKa of a free amino acid can vary upon its
incorporation into a peptide and protein sulfhydryl group pKa values can be very
different.
Additionally, Pep-TNB substrates were designed thinking they would mimic the
activity of the acyclic Sec peptides. This assumption correlated well with the DmTR∆8
enzyme, however, Figure 21B shows that the mTR3∆8 enzyme pH optimum was
lowered 1.5-2.0 units compared to the DmTR∆8 enzyme. Why might this be? First, as
stated above the Sec residue pKa must be higher that than that of the reported for free Sec.
Second, the pKa of the CysCT thiol must be lower in the mTR3 enzyme while DmTR must
be elevated in comparison to each other. This property would allow for the ring to be
opened

at

lower

pH

in

the

case

of

the

mammalian

enzyme.

Since the truncated TRs used in this study resemble GR, it is suitable to use the
pKa values of yeast GR since there is high degree of homology among the active site
titratable groups. An area for future study would be to determine the pKa of the truncated
TR enzymes and compare their values to the GR. It was demonstrated that a human
TR∆16 could not regain GR activity (87). The environment surrounding the active site
pocket was negatively charged compared to the positively charged GR active site. This
undoubtedly would have an effect upon the TR active site pKa’s.
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There are several implications for mTR3’s ability to function at low pH. One
possibility is for the role in redox signaling as suggested by Sun et al (77). When
hydrogen peroxide levels rise in the cell, TR becomes oxidized. Upon accumulation of
oxidized TR, cellular targets remain oxidized. The ensuing build up of reactive oxygen
species, can cause activation of redox regulating pathways such as the through apoptosis
signal-regulating kinase 1 (97).

Second, the cellular milieu contains several small

molecules (hydrogen peroxide (59), dehydroascorbate (98), selenodiglutathione (99)),
that have almost exclusively be shown to be capable of reduction by mTR3. The ability
of mTR3 to still form a charge transfer complex at low pH, and open the C-terminal ring,
could allow for prolonged ability to control the build up of hydrogen peroxide in the
cellular milieu. This could be an important biological function since this is a
mitochondrial enzyme; the respiratory chain is constantly producing hydrogen peroxide.
Base on the data presented herein, Figure 23 diagrams a proposed mechanism of
TR. Of the two residues in the Cys-Cys or Cys-Sec dyad, the C-terminal residue is
thought to be the nucleophile (X = S or Se) in the attack on the disulfide bond of Trx
(Figure 23B). Once the mixed disulfide (or selenylsulfide) bond forms between enzyme
and substrate (Figure 23C), the adjacent Cys residue must then act to resolve the
complex and form the eight-membered ring. NMR data shows that substitution of a Se
atom in the ring makes it larger and stabilizes the trans form of the ring. Thus for Seccontaining enzymes, this resolution step would be more facile. Once the eight-membered
ring forms, it must be opened by an attacking sulfur nucleophile (CysIC) as shown in
(Figure 23D). Our X-ray structure of DmTR shows that this must happen when the ring

101

is in a cis conformation (Figure 24). This cis conformation can be formed because the
eight-membered ring can equilibrate between cis and trans ring forms. Thus I propose
that a key difference between the two classes of enzymes is that Se-TRs can utilize the
trans form of the ring because the Se atom does not need to be protonated. The presence
of Se would also eliminate a trans to cis conformational switch that is needed in the CysTRs.
This report strongly argues in favor of our hypothesis, in which Sec incorporation
into mammalian TR active site is essential for activity because of its superior ability to
act as leaving group in the ring opening step of the reaction mechanism, not its enhanced
nucleophilicity towards Trx.
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A

B

Figure 22: Mechanism of truncated TR toward cyclic and acyclic peptide substrates.
The peptide substrate is positioned in the active site such that nucleophilic CysIC thiolate
can attack the Cys1 position, and cause the release of X (pink). A.) In the case of the
cyclic peptide, when X = Cys, the ring is critical for positioning X near the conserved
His, to receive a proton to stabilize the leaving group. When X = Sec, the position of the
ring near the His is not as critical. B.) In the case of the acyclic peptide, when X = Cys,
protonation of X is unlikely to occur due to the “floppy” nature of the peptide. However,
when X = Sec, protonation does not need to occur for stabilization due to its lowered pKa.
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A

B

C

D
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Figure 23: Mechanism of Thioredoxin Reductase.
(A) Proposed pathway for transfer of electrons to Trx by TR. The Cys residue that
interacts with the flavin cofactor is labeled as “CT” (charge-transfer), while the Cys
residue that acts as the interchange residue is labeled “IC”. Once the interchange Cys
becomes reduced by the flavin cofactor, it initiates attack on the eight-membered ring
formed by either adjacent Cys residues (DmTR and CeTR2) or adjacent Cys and Sec
residues (mTR3) on the C-terminus on the opposing subunit. I refer to this step in the
reaction mechanism as the “ring opening” step and is highlighted in red in the diagram.
Once this ring is reduced, the attacking nucleophile (either a sulfur atom or a selenium
atom – labeled as X), initiates attack on the disulfide bond of Trx (B). The N-terminal
Cys of the dyad would then “resolve” the mixed disulfide formed between TR and Trx
and is thus labeled as “Res”. The “prime” designation indicates residues that are on the
adjacent subunit. (C) Diagram of the TR/Trx complex formed when the attacking
nucleophile (either S or Se) attacks the disulfide bond of Trx. The adjacent Cys residue
then attacks to resolve this complex, releasing product and forming the oxidized, eightmembered ring. (D) The eight-membered ring is then reduced by CysIC. CysIC can attack
the N-terminal sulfur atom (pathway 1) or the C-terminal atom (S or Se, pathway 2). I
have argued here and previously (65, 88) for pathway 1). Termaa is the C-terminal amino
acid (either Gly or Ser).
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A

B

Figure 24: Conformational Ring Switching
The Cys-Cys eight-membered ring has been implicated in switching between trans (A)
and cis (B) conformations. NMR data indicates that Se incorporation results in
stabilization of the trans conformation limiting switching.
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Appendixes
A. Abbreviations
1

A280, absorbance at 280nm; A412, absorbance at 412nm; A460, absorbance at 460nm;

AA1-AA2-AA3-AA4-Sec1-Cys2-AA7-AA8, peptide sequence for switch mutant; ADP,
adenosine diphosphate; βME, β-mercaptoethanol; C. elegans, Caenorhabditis elegans;
CeTR2, mitochondrial TR from Caenorhabditis elegans; CeTR2∆8, truncated
mitochondrial

TR

from

Caenorhabditis

elegans;

CeTR2-GCCG,

full-length

mitochondrial TR from Caenorhabditis elegans indicative of tetrapeptide motif;
CVNVGC, conserved N-terminal redox site with sequence Cys-Val-Asn-Val-Gly-Cys;
Cys, cysteine; Cys1, N-terminal cysteine of dyad; Cys2, C-terminal cysteine of dyad;
CysIC, interchange cysteine; CXXC, the tetrapeptide motif Cys-Xaa-Xaa-Cys; D.
melanogaster, Drosophila melanogaster; DEAE, diethylaminoethyl; DmTR, TR from
Drosophila melanogaster; DmTR∆8, truncated TR from Drosophila melanogaster;
DmTR-SCCS, full-length TR from Drosophila melanogaster indicative of tetrapeptide
motif; DmTrx, cognate Trx from Drosophila melanogaster; DTNB, 5,5’dithio-bis(2nitrobenzoic

acid);

DTT,

dithiothreitol;

E.

coli,

Escherichia

coli;

EDTA,

ethylaminediamine tetraacetic acid; Gly, glycine; GR, glutathione reductase; Grx,
glutaredoxin; GSH, glutathione, reduced; GSH I, interchange glutathione; GSH II, first
leaving group glutathione; GSSG, glutathione, oxidized; H2O2, hydrogen peroxide;
HEPES, N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; IPTG, isopropyl-β-Dthiogalactopyranoside; kcat, turnover number; kDa, kilodaltons; KM, Michaelis constant;
LB, Luria-Bertani media; MDS, mixed disulfide; MES, 2-(4-morpholino)-ethane sulfonic
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acid; MESNA, 2-(N-morpholino)ethanesulfonic acid sodium salt;

MOPS, 3-(N-

morpholino) propane sulfonic acid; Mr, molecular ratio; mTR3, mitochondrial TR from
mouse; mTR3∆8, truncated mitochondrial TR from mouse; mTR3-GCUG, full-length
mitochondrial TR from mouse indicative of tetrapeptide motif; MW, molecular weight;
MWCO, molecular weight cut off; NaCl, sodium chloride; NADPH, β-nicotinamide
adenine dinucleotide phosphate, reduced; Ni-NTA, nickel nitrilotriacetic acid; NMA, Nmethylmercaptoacetamide; O.D., optical density; PCR, polymerase chain reaction; PDB,
Protein Data Bank; Pep-TNB, AA1-AA2-AA3-AA4-AA5-Cys1-S-S-TNB (5-thio-2nitrobenzoate) mixed disulfide; PfTR, Plasmodium falciparum TR; PRTQGCCG, the
octapeptide Pro-Arg-Thr-Gln-Gly-Cys-Cys-Gly; PTPASCCS, the octapeptide Pro-ThrPro-Ala-Ser-Cys-Cys-Ser; PTVTGCUG, the octapeptide Pro-Thr-Val-Thr-Gly-Cys-SecGly; S, sulfur atom; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel
electrophoresis; Se, selenium atom; Sec, selenocysteine; Sec1, N-terminal selenocysteine
of dyad; Sec2, C-terminal selenocysteine of dyad; Ser, serine; TB, terrific broth; TE, Tris
EDTA buffer; TNB-S-, 5-thio-2-nitrobenzoate anion; TR, thioredoxin reductase; Tris,
tris-(hydroxymethyl)aminomethane; Trx, thioredoxin; U, the one letter code for
selenocysteine; UGA, sense codon for translation of Sec; WT, wild type; X, represents
either (S) sulfur or (Se) selenium atom.
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